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GENERAL INTRODUCTION 
In spite of all efforts and modem scientific developments, bovine respiratory 
disease (BKD) continues to be an enigma for the cattle industry of many countries 
including the United States of America. It has been estimated that 40-80% of all 
diseases of catde involve the respiratory system (Lillie, 1974). In the United States 
alone it causes a loss of 250-750 million dollars annually (Loan, 1983). Baker (1984) 
cited a 1977 Livestock Conservation Institute estimate of a one billion dollar loss due 
to BRD per year in North America. 
Bovine respiratory syncytial virus (BRSV) is one of the most frequently occurring 
and virulent etiological agents of respiratory tract disease in calves. It is considered 
to be a major contributor to the incidence of respiratory tract disease in nursing beef, 
feed lot and dairy calves (Duncan and Potgieter, 1993; Kimman et al., 1988; Baker 
and Frey, 1985). The virus causes an acute pneumonia with high morbidity and 
appreciable mortality in some herds. There are also indications that BRSV infection 
can predispose to bacterial pneumonia resulting in increased severity of the disease 
(Al-Darraji et al., 1982). Seroepizootiological surveys and virus isolation have 
indicated that exposure of catde to BRSV is widespread in many countries 
(Pemthaner et al., 1990; Burgu et al., 1990; Kimman et al., 1988; Baker et al., 
1986; Mahin et al., 1985; Elazhary et al., 1980). 
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Bovine respiratory syncytial virus is an enveloped, single stiranded, negative sense 
RNA virus that has been classified with human respiratory syncytial virus (HRSV) as 
Pneumovirus in the family Paramyxoviridae (Kingsbury et al., 1978). The viruses 
are antigenically related (Lerch et al., 1989) and cause the greatest morbidity in their 
respective species during the first six months of life when maternal immunity is still 
present. Reinfections are conunon and difficulties have been encountered in 
providing protection through live or inactivated vaccines against respiratory syncytial 
viruses (RSV) (Stott and Taylor, 1985). A major limitation of these vaccines is that 
maternally derived immunity to BRSV suppresses an active inunune response to 
vaccination in calves (Kimman et al., 1987; Westenbrink et al., 1989). The basis for 
this suppression is not well understood. It may result from the blocking effect of the 
specific anti-viral antibodies. The phenomenon of antibody-mediated 
immunosuppression has been demonstrated in cotton rats in which the passive transfer 
of hyperimmune RSV antiserum suppressed the inunune response to RSV 
glycoproteins but not to vaccinia virus antigen ^urphy et al., 1988). 
The genome of the respiratory syncytial virus codes ten proteins, including two 
nonstructural (IB and IC) and eight structural proteins (Mallipeddi et al., 1990; 
Mcintosh and Chanock, 1990). The major glycoprotein (G), fusion protein (F), lA 
protein and 22Kd proteins are components of the viral envelope. The G protein 
mediates attachment of the virion to the cell membrane. The F protein mediates 
fusion between the cell membrane and the viral envelope. The nucleocapsid contains 
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the nucleocapsid protein (N), the phosphoprotein (P), and the large protein (L). The 
matrix protein (M) forms a structural layer between the envelope and the 
nucleocapsid (Mcintosh and Chanock et al., 1990). Antibodies to all the structural 
proteins develop in convalescent calves (6 to 7 months old), but these are 
predominantly directed against the F and N proteins (Westenbrink et al., 1989). 
Similarly, in a limited study, 2 to 3 week old calves have been reported to have 
moderate levels of maternal antibodies to the F and N proteins against BRSV 
(Westenbrink et al., 1989). However no definite studies appear to have been 
published regarding the specificity and mean duration of maternal antibodies in 
calves. 
A number of workers have analyzed die antibody response to N protein of HRSV 
in experimental animals with variable results. King et al. (1987) reported that N 
protein expressed in vaccinia virus afforded a significant degree of protection in 
BALB/c mice. Although vaccination with the recombinant expressing N protein 
resulted in a significant reduction in titer in the lung of the mice following live virus 
challenge, the protection was not as solid as provided by G and F proteins expressed 
and used similarly (Stott et al., 1986; Wertz et al., 1987). Peretz et al. (1992) have 
reported that G and F, but not N protein induces protection in BALB/c mice. 
Immunity induced by G or F proteins lasts longer than that induced by N protein 
(Connors et al., 1991). The N protein probably plays a role in RSV-specific 
cytolytic T-cell responses (Mcintosh and Chanock, 1990) because N protein served as 
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a target for RSV-specific Tc cells in both mouse and human studies (Bangham et al., 
1986; King et al., 1987). It is therefore reasonable to assume that the N protein of 
BRSV may also serve as a target for bovine Tc cells. These observations suggest 
that N protein is not as immunogenic as the G and F proteins and thus maternal 
antibody to the N protein may drop below detectable level sooner than the antibody 
to the F protein. Our own preliminary studies (unpublished data) in which the 
specificity and duration of maternal antibody was studied suggested that antibody to 
the N protein drops below detectable levels before antibody to the F protein. 
Consequently, it may be possible to immunize calves with the N protein in the 
presence of levels of maternal antibody that interfere with responses to other viral 
proteins. The role of nucleocapsid protein as a protective antigen has also been 
described for the morphologically similar influenza virus (Wraith et al., 1987). 
As far as ascertainable from the literature the N protein of BRSV has not been 
used as immunogen in any form. Therefore the purpose of this study was to: 
1) study the morphogenesis of BRSV strain 375 grown in Vero cells, 
2) generate monoclonal antibodies (MAbs) against the N protein of BRSV and to 
characterize these by ELISA, indirect immunofluorescence, epitope mapping, and 
radioimmunoprecipitation assay, and 
3) use solid matrix antibody-antigen complexes containing N protein of BRSV to 
investigate the immunogenicity of the N protein and to determine its carrier effect on 
the subsequent vaccination (challenge) with heat inactivated virus. 
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Dissertation Organization 
This dissertation consists of a general introduction, a review of literature, three 
manuscripts, a general summary, and literature cited. The first manuscript was 
written for submission to Archives of Virology. The second and third manuscripts 
were written for submission to the American Journal of Veterinary Research. The 
format used for literature cited in the manuscripts is according to the requirement of 
each journal. Literature cited within the general introduction, literature review, and 
general summary is presented at the end of the dissertation. 
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LITERATURE REVIEW 
Historical Bacl^ound and Prevalence of the Virus 
In 1956 Morris, Blount and Savage reported the isolation of an agent they 
suspected of causing an epizootic of respiratory disease in a colony of chimpanzees. 
Since it caused clinical signs like coryza they luimed this virus chimpanzee coryza 
agent (CAA). The epizootic was not severe, involving some 20 animals; however, 
further studies with the virus have been very extensive, opening broad areas in 
human as well as bovine respiratory disease research. Experimental infection in a 
number of laboratory animals including day-old mice, weanling hamsters, young 
rabbits, guinea pigs, etc. indicated that only chimpanzees were affected by this virus. 
A serological survey indicated that the CAA was not antigenically related to many 
other viruses being studied at that time. In the course of this study, a laboratory 
worker developed a moderate respiratory infection. Although CAA could not be 
isolated from him, there was serological evidence that this virus was involved in the 
illness. This finding led to a serological survey which indicated a broad antibody 
response in the human population, which in turn stimulated the isolation of CAA or a 
similar agent from humans with respiratory disease. 
The following year antigenically identical viruses were isolated (Chanock et al., 
1957) from two infants with lower respiratory tract disease. These isolates were 
named the Snyder and Long strains after the patients from whom they were isolated. 
The cytopathic effects (CPE) of these isolates were indistinguishable from those 
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produced by CAA. A close antigenic relationship was found between CAA and the 
new isolates by complement fixation and cross-neutralization tests. Since these 
agents and CAA appeared to be antigenically identical, and because of the 
characteristic syncytium production in cell culture, the isolates were grouped together 
as respiratory syncytial viruses (Chanock et al., 1957). 
Like human respiratory syncytial virus (HRSV), antibodies to bovine respiratory 
syncytial virus (BRSV) were also reported before isolation of the virus. In 1968 
English investigators working on HRSV realized that the calf serum they were using 
in tissue culture medium contained lectors that inhibited syncytium formation in 
HRSV-infected cells. Subsequent studies established that these inhibiting factors 
were specific antibodies and thus indicated that the same or a closely related virus 
must be present in cattle (Doggett et al., 1968). This apparentiy set the stage for 
isolation of a respiratory syncytial virus from cattie. 
At the beginning of February 1967, an acute febrile respiratory disease was 
observed in cattle on several iiEuins in the canton of Geneva, Switzerland. In mid-
February, the epizootic disease spread to the cattle of three of the five farms of the 
small village of Avusy. Paccaud and Jacquier (1970) published a report of this 
outbreak. All animals less than seven years of age on two farms showed clinical 
signs of an acute respiratory disease. Interestingly, older cattle remained apparentiy 
healthy although they were in close contact with the sick animals. Although the first 
symptoms of the disease appeared serious, the course was relatively benign. It seems 
8 
worth mentioning that no respiratory or feverish disease was observed in the human 
beings who cared for the catde, or who lived on the affected farms, or who visited 
them before or soon after the outbreak. 
During the course of the investigation twelve specimens (conjunctivo-nasal swabs) 
were collected from calves and heifers on two farms. Two viruses were isolated one 
each from a calf and a heifer on the two forms. It soon became apparent that the 
isolates were identical and, ftirthermore, that they manifested many biological 
characteristics similar to HRSV isolates. On the second passage in primary bovine 
embryonic kidney cells syncytia began to appear after twelve days of incubation at 
36°C, The first indication of CPE was that of granular, ballooned cells, progressing 
to syncytium formation with additional incubation. With additional passages CPE 
was noted to develop rapidly in 5-6 days. 
The physical and chemical properties of these bovine isolates closely resembled 
those of human isolates. They were found to be very heat labile and sensitive to low 
pH and lipid solvents. Serological studies were conducted with acute and 
convalescent serum samples of infected catde. There was seroconversion in both 
affected herds, including the two animals from which the viruses were isolated. This 
was accepted as evidence for a bovine origin of the isolates and that these isolates 
were involved in the respiratory outbreak. Cross-neutralization tests with the bovine 
isolates and a human RS virus using guinea pig antiserum were also conducted. The 
results indicated that the bovine and human viruses were antigenically closely related 
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but not identical. Further serological studies revealed that one-third of all bovine 
sera tested had serum neutralizing antibodies to the bovine isolates. One of the 
bovine isolates was neutralized by over SO percent of the human sera tested, further 
indicating the close relationship of the two viruses. From these studies and 
observations, the investigators concluded that their isolates were bovine respiratory 
syncytial viruses. 
Later, Inaba et al. (1970) described a respiratory epizootic that swept through 
cattle in Japan during 1968 and 1969. They clearly documented that bovine 
respiratory syncytial virus was involved in this outbreak and that it was antigenically 
closely related to HRSV. In the same year Wellemans et al. (1970), reported 
isolation of BRSV from cattle in Belgium. A subsequent report of a serological 
survey of catde in Belgium indicated that nearly 40 percent of the animals tested had 
an antibody titer to BRSV (Wellemans et al., 1971). In 1971 Jacobs and Edington 
reported isolation of BRSV from cattle in England. A few years later Koves and 
Bartha (1976) reported isolation of BRSV from calves in Hungary. 
A serological study with various animal species was conducted to detect serum 
antibodies to BRSV in Canada (Berthiaume et al., 1973). Although it was a limited 
survey, there was an indication of antibody titers not only in cattle, but also in sheep. 
It was concluded from this study that, since a high percentage of sheep did have RSV 
antibodies, sheep might serve as an experimental model for the study of HRSV. 
Serum antibodies have also been reported in fallow deer in Italy (Giovannini et al., 
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1988); white-tailed deer, mule deer, and hunter killed pronghoms in the United States 
(Johnson et al., 1986); Peruvian alpaca (Rivera et al., 1987), and goats in Zaire 
(Jetteur et al., 1990). Caprine respiratory syncytial virus has been isolated from a 
herd of pygmy goats (Smith et al., 1979). Serum antibodies have also been detected 
in cats, dogs and pigs (Baker and Frey, 1985). 
The first isolations of BRSV from cattle in the United States were reported in 
Iowa and Missouri in 1974 by Smith et al. (1974) and Rosenquist (1974) respectively. 
Since then respiratory tract disease associated with BRSV has been reported from 
many countries. Serological surveys in Morocco (Mahin et al., 1985), Canada 
(Moteane et al., 1978; Elazhary et al., 1980; Lynch and Derbyshire 1986; 
Donkersgoed et al., 1993), Germany (Pemthaner et al., 1990), and Turkey (Burgu et 
al., 1990) have indicated the prevalence of BRSV to be 70.4%, 35.9% to 95%, 
17.4%, and 46.12%, respectively. Virus isolation and serological studies have 
provided evidence that BRSV causes respiratory disease outbreaks in cattle 
worldwide. 
Infection with BRSV apparently is common, as indicated by a high percentage of 
cattle with serum antibodies to BRSV in the United States. Antibody prevalence to 
BRSV has been reported to be 81% in Iowa (Smith et al., 1975), 38% in Maryland 
(Mohanty et al., 1975), 67% in Alabama (Rossi and Kiesel, 1974), 76.3% in 
Oklahoma (Potgieter and Aldridge, 1977) and 65.5% in Minnesota (Baker et al., 
1985). 
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It has become apparent that BRSV plays a significant role in the bovine 
respiratory disease complex. Serum antibodies are not only high in cattle but the 
limited literature indicates considerable prevalence in sheep as well. A flock of 373 
in Minnesota were found to have 52.5% seropositive ewes (Goyal et al., 1988). The 
respiratory syncytial virus has also been isolated from sheep (Smith et al., 1974; 
LeaMaster et al., 1983) 
Pathogenesis 
The pathogenic mechanisms involved in BRSV infections remain poorly defined 
and not well understood. Infected cattle transmit BRSV to susceptible cattle by 
aerosolized secretions and the virus gains entrance into a new host through the 
respiratory tract (Kahr, 1981). The BRSV replicates in the cells of the nasal mucosa, 
pharynx, trachea, and lungs of the calves exposed to experimental infection by the 
respiratory route (McNulty et al., 1983; Thomas et al., 1984; Castleman et al., 
1985a). However, Trigo et al. (1984) detected viral antigen in the epithelial cells of 
the bronchioles as well as alveoli but they could not demonstrate viral antigen in the 
cells of nose, trachea, and bronchi. Viral antigen has also been demonstrated in 
alveolar macrophages (Casdeman et al., 1985a). Trigo et al. (1985) reported 
abortive BRSV infections of bovine pulmonary alveolar macrophages in vitro. 
Scanning electron microscopy has demonstrated destruction of ciliated respiratory 
epithelium in calves 8-10 days after experimental infection (Eis, 1979). These 
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findings indicate that pulmonaiy clearance may be compromised by BRSV allowing 
secondary pulmonary infection by agents present in Ihe upper respiratory tract. 
BRSV and Pasteurella hemolytica have been shown to have synergistic pathogenic 
effects under experimental conditions in lambs (Al-Darraji et al., 1982; Trigo et al., 
1984). Calves infected with lungworms had more severe clinical signs after infection 
with BRSV than non-parasitized calves (Verhoeff et al., 1988). 
Although there are reports of respiratory disease outbreaks in catde in which the 
only virus identified was BRSV, other investigators have reported concurrent 
infection with other viruses such as bovine virus diarrhea (BVD), infectious bovine 
rhinotracheitis (IBR), parainfluenza virus 3 (PI3) and adenovirus type 3 (Bryson et 
al., 1979; Elazhary et al., 1980; Johnson et al., 1981; Bryson et al., 1983; 
Steinhagen and Heckert, 1988). Lehmkuhl and Gough (1977) speculated that BRSV 
infection may facilitate infection by other viruses. 
A biphasic pattern of clinical signs and the response to treatment with 
corticosteroids and antihistamines has given rise to a speculation that hypersensitivity 
may be involved in pathogenesis of BRSV infections in cattle (Bohlender et al., 1982; 
Frey, 1983). Epizootic evidence does not support this hypothesis since during the 
seasonal occurrence of the disease only calves not present during previous epizootics 
are affected (Verhoeff et al., 1984). Furthermore, experimental infection of calves 
followed by superinfection 10 days later did not appear to cause a severe disease; 
rather the calves appeared to be resistant to the second infection (Ciszewski et al., 
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1987). The role of IgE antibodies in the pathogenesis of BRSV has yet to be 
determined. Limited studies indirectly implicate IgE antibody in the pathogenesis of 
BRSV. Stewart and Gershwin (1989) reported that, when calves previously 
vaccinated were challenged with the virus, there was a strong correlation between 
disease signs and histamine concentration in nasopharyngeal exudate. They also 
reported a correlation between signs of the disease and BRSV-IgE antibody 
concentration in the lung lavage fluid; this was true for the vaccinated group but not 
for the unvaccinated group. Plasma concentrations of histamine have also been 
reported to be significantly greater in calves infected with BRSV than in uninfected 
calves (Gershwin and Girl, 1992). 
Clinical Features 
The hallmark of RSV infections is their recurrence and variability in clinical 
signs and disease (Mcintosh and Chanock, 1990). The virus is a major cause of 
lower respiratory tract disease in catde and humans. In both species major problems 
due to RSV occur during the first six months of life when maternal immunity is still 
present (Stott and Taylor, 1985). 
The cattle outbreak in Japan which affected 40,000 animals was characterized by 
anorexia, depression, respiratory distress, cough, nasopharyngeal secretions, and 
foamy with sometimes blood-stained saliva. The mortality rate in this outbreak was 
0.26% (Inaba et al., 1970). Paccaud and Jacquier (1970) reported an outbreak in 
14 
cattle that developed rapidly in Svtdtzerland. In most cases, only febrile involvement 
of the upper respiratory tract with nasal discharge and cough was noted. In about 
one-third of the cases however, a relatively high fever up to 41.5°C developed and 
discrete signs of bronchopneumonia were observed. A surprising observation was 
that the most severely ill animals were cows (aged less than 7 years) and not calves. 
Older catde remained apparendy healthy although they were in close contact with the 
sick animals. The disease subsided in 3 to 5 days in calves and heifers and 8 to 10 
days in cows. There were no deaths or serious complications. 
BRSV affects all types of catde including adults (Inaba et al., 1970; Paccaud and 
Jacquier, 1970), weaned calves (Smith et al., 1975; Frey, 1983; Gillette and Smith, 
1985) and calves (Rosenquist, 1974; Pirrie et al., 1981; Elazhary et al., 1982). The 
severity of the disease varies considerably from group to group, and within groups. 
Clinical signs in weaned calves have been described (Bohlender, 1981; Bohlender et 
al., 1982). Early signs included anorexia and a rapid increase in the frequency and 
severity of coughing. Respiratory signs were most prominent and included nasal and 
lacrimal discharges and increased respiratory rate. Elevated rectal temperatures 
ranged from 40-42.2°C. The authors reported that the early stage of the disease is 
difficult to detect since calves with increased body temperature often brighten up 
when approached. If the early stage is missed the disease can progress rapidly and 
calves may be found dead. Later stages of the disease are characterized by marked 
dyspnea, with mouth breathing, frothing of saliva and a dry hacking cough. 
Subcutaneous edema was first observed as a slight puffiness around the eyes, and as 
it became more severe there was swelling in the mandibular area, throatlatch and 
neck. Diarrhea has been reported but tends to be transient and may be followed by 
constipation because of decreased water and feed intake. Morbidity in a herd is 
usually high and duration of the disease may range from 10-14 days. Mortality is 
variable and may range from 0% to 20% (Holzhauer, 1979). If the disease is not 
recognized promptly while in the early stage, mortality may increase. Secondary 
bacterial pneumonia is a common occurrence in association with BRSV infections. 
Subclinical and asymptomatic BRSV infections have also been reported (Rossi 
and Kiesel, 1974; Bohlender et al., 1982). In some cattle herds two stages of the 
disease have been described. The first stage is expressed as a mild respiratory 
disease characterized by nasal and lacrimal discharge followed by quick recovery. 
The second stage follows in several days to several weeks with a sudden onset of 
severe dyspnea. Death occurring in the second stage is associated with atypical 
interstitial pneumonia (Wellemans et al., 1978; Baker and Frey, 1985). 
Most of the time experimental infections have been unsuccessful in producing a 
disease process characteristic of natural disease in calves. Experimental infections 
have resulted in mild respiratory disease characterized by fever, rhinitis and 
sometimes nasal discharge and cough (Eddington and Jacobs, 1970; Mohanty et al., 
1975; Smith et al., 1975; Thomas et al., 1984; Castleman, et al., 1985a). However, 
Bryson et al. (1983) were successful in producing a severe respiratory tract disease 
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characterized by coughing, tachypnea, and hyperpnea in young calves. They gave the 
virus to calves by a combined intranasal (i/n) and intratracheal (i/t) route for four 
consecutive days. Similarly Ciszewski et al. (1991) induced severe respiratory tract 
disease in one-month-old calves that were colostrum-fed and seropositive to BRSV. 
They also administered the virus by a combined respiratory tract route (i/n, i/t) for 
four consecutive days. Although ovine respiratory syncytial virus has been isolated 
from sheep, widespread outbreaks have not been reported. Experimental inoculation 
of lambs with BRSV causes a mild clinical response consisting of a transient pyrexia, 
hyperpnea, slight nasal discharge, coughing and dullness (Al-Darraji et al., 1982; 
Trigo et al., 1984; Sharma and Woldehiwet, 1990, 1990a, 1992). 
Characteristics of Respiratory Syncytial Virus 
Morphology: The study group on Paramyxoviridae, Vertebrate Virus Subconunittee 
of the International Committee on Taxonomy of Viruses has placed the three genera 
Paramyxovirus, Morbillivirus and Pneumovirus in the family Paramyxoviridae. The 
genus Pneumovirus includes HRSV (type species), BRSV, and pneumonia virus of 
mice. Recently, turkey rhinotracheitis virus has also been placed in the genus 
Pneumovirus (Pringle, 1991). According to the Committee the overall shape of 
HRSV is pleomoiphic, usually roughly spherical, but filamentous forms are frequent. 
Pleomorphic and spherical forms are 80-500 nm in diameter and filamentous forms 
are 60-110 nm in diameter and 5 /xm in length. The virus particles have a 7-15 nm 
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thick envelope covered with 10-12 nm projections (Kingsbury et al., 1978). 
Armstrong et al. (1962) reported that filamentous forms have a uniform width of 60-
70 m/i, and up to 2 fim in length and that they are bounded by a layer of 
exceptionally high density. They further concluded that transection of filaments 
would naturally account for at least some of the circular profiles in the micrographs; 
thus truly spherical particles amounted, at most, to a minority of those actually seen. 
Other workers (Norrby et al., 1970; Bachi and Howe, 1973; Berthiaume et al., 1974) 
have also reported the virus particles of HRSV to be pleomorphic with a variable 
diameter of 100-350 nm. In addition to the pleomorphic forms, filamentous forms 
were also frequently observed with dimensions of 60-110 nm diameter and up to 5 
fim length. The filamentous forms predominated. Berthiaume et al. (1974) also 
suggested that the spherical to oval forms are cross and oblique sections of the 
filamentous forms. The lipid bilayer membrane encloses an RNA nucleocapsid which 
contains a nonsegmented, negative-strand RNA genome (Huang and Wertz, 1982) 
and the virus matures while budding through the cell membrane (Mcintosh and 
Chanock, 1990). 
Ito et al. (1973) studied BRSV in calf kidney cell cultures and reported that in 
negatively-stained preparations the virus particles showed great pleomorphism. Many 
virus particles appeared roughly spherical, others were more or less elongated or 
distorted. The overall diameter varied fi-om 80-450 mpi and intact virions had a thick 
membrane (70-150 A°), covered with mostly club-shaped projections, measuring 130-
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170 A° in length. In ultrathin sections spherical particles measuring 80-130 mfi in 
diameter along with filamentous forms of 100-130 mju in diameter with variable 
length were seen. They also observed dots with a diameter of 11-15 m/x, as 
previously reported by Nonby et al. (1970) in HRSV, within the budding virus 
particles. Based upon the structure, as well as the site and mode of maturation of 
BRSV, HRSV, and pneumovirus of mice they proposed that these three be grouped 
together as metamyxovixuses. 
Moussa (1994) has also reported that the BRSV particles are filamentous in form, 
about 80-120 nm in diameter, and variable in length. Belanger et al. (1988) studied 
the structure of BRSV grown in a continuous cell line of ovine kidney (OIQ origin 
and reported the presence of well-defined bridges between the virus particles. 
Similar bridges were also observed between BRSV particles grown in Vero cells or 
bovine kidney cells. In contrast no such bridges were apparent between HRSV 
particles (Long strain) grown under similar conditions. They further reported that the 
BRSV particles, like HRSV, appeared to be surrounded by an 7.5 ±1.7 nm 
electron-dense membrane and were mainly filamentous forms. Their length varied 
considerably, with values reaching up to several micrometers, but the diameter was 
relatively constant at 94.6 ± 5 nm. 
Genomic organization: The genome of HRSV is a single negative-sense strand of 
RNA which is composed of 15,000 nucleotides (Collins et al., 1987). It contains one 
promoter and ten genes that are transcribed as a single unit from the promoter at the 
19 
3' end of the genome (Dickens et al., 1984). Ten unique mRNAs are transcribed and 
each codes for a unique protein (Huang et al., 1985). The order of the transcription 
is 3' 1C-1B-N-P-M-1A-G-F-22K-L 5' (Collins et al., 1987). The HRSV genes are 
nonoverlapping except for the last two genes in the 3 —5' order. This overlapping by 
68 nucleotides results in down regulation of L protein synthesis (McLitosh and 
Chanock, 1990). Like HRSV the BRSV genome also encodes for ten different 
mRNAs. The electrophoretic pattern of BRSV mRNAs is similar to that of HRSV 
(Lerch et al., 1989; Mallipeddis et al., 1990). 
Viral proteins: Extensive experimentation has been conducted to define the 
molecular biology of HRSV. Ten viral proteins (Table 1) have been identified: large 
(L), glycoprotein (G), fusion (F), nucleocapsid (N), phosphoprotein (P), matrix (M), 
14K (IB), 22K (M2), 15K (IC), and 9.5K (lA). Two of the proteins (1B,1C) are 
nonstructural and the remaining eight are structural. The G, F, lA, and 22K proteins 
are associated with the membrane of infected cells and the virus envelope. The G, F, 
and lA are glycosylated (Kimman and Westenbrink, 1990). The 22K protein is not 
glycosylated and its exact location in the virion is not known (Mcintosh, 1978); it 
may be a second matrix protein (M2). The functions of 1A and 22K are not known 
(Mcintosh and Chanock, 1990). 
The G protein has a high carbohydrate content, as is indicated by the fact that its 
protein moiety is relatively small (32.6 Kd) in relation to the mature fully processed 
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Table 1. Structural and nonstructural proteins of HRSV, strain Aj of subgroup A 
Protein/ 
designation 
MW 
(kllodaltons) Location Function 
Additional known 
properties 
Nsi (icy 15.6 Not in virion Not known Slightly acidic 
NS2 ( I B f  14.7 Not in virion Not known Basic 
N 43.5 Nucleocapsid Structural protein of 
nucleocs^sid 
Abundant; tightly 
complexed with 
genomic RNA 
P 27.1 Nucleocapsid Component of 
polymerase 
complex? 
Phosphorylated; 
relatively acidic 
M 28.7 Inner aspect 
of viral 
envelope 
Inner lining of viral 
envelope 
Relatively basic, 
moderately 
hydrophobic 
SH (1A)« 15 and 
21-30 
Surface of 
infected cell 
Not known Strongly hydro-phobic 
core of 28 amino acids. 
G 84-90 Surface of 
viral envelope 
Attachment to 
host cell receptors 
High content of 
carbohydrate, 90% of 
which is 0-linked to 
serine and threonine. 
F 68-70 Surface of 
viral envelope 
Fusion of viral 
envelope with host-
cell envelope; 
syncytium formation 
Cleaved proteo-
lytically to yield 
disulfide linked Fj (20 
kd) and F, (48 kd). 
M2 (22K)« 22.2 Viral envelope Not known Hydrophilic and very 
basic. 
L 250 Nucleocapsid Polymerase of 
nucleocapsid? 
Low abundance in 
virions and infected 
cells 
"Former designations. 
Source: Mcintosh and Chanock, 1990. 
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protein (84-90 Kd) (Wertz et al., 1985). It mediates attachment of the virion to the 
cell membrane (Levine et al., 1977). The F (68-70 Kd) protein is glycosylated, and 
is composed of two disulfide-linked subunits, F, and Fj (Dubovi, 1982; Lambert and 
Pons, 1983; Huang et al., 1985). The F protein mediates fusion between the cell 
membrane and the viral envelope. Many monoclonal antibodies that precipitate this 
protein inhibit cell to cell fusion caused by RSV (Walsh and Hruska, 1983). Three 
proteins N (43.5 Kd), P (27.1 Kd), and L (250 Kd) are located in the RSV 
nucleocapsid. N is an abundant protein that serves a structural function, whereas the 
other two probably play roles in transcription and replication of viral RNA that 
remain to be defined (Mcintosh and Chanock, 1990). The 28.7 Kd M is present in 
detergent-solubilized cores but not in nucleocapsids, which suggests that it is 
analogous to the matrix protein of other RNA viruses (Mcintosh and Chanock, 1990). 
In contrast, until recendy very little was known about the molecular biology of 
BRSV. In a preliminary report Cash et al. (1977) compared the polypeptides of 
HRSV and BRSV and demonstrated six BRSV-specific polypeptides that migrate very 
closely to F, N, P, M, 24K and lOK proteins of HRSV. Lerch et al. (1989) 
identified nine polypeptides of BRSV in infected cells by comparing the proteins of 
BRSV- and HRSV-infected cells and by immunoprecipitation and western 
immunoblot assays using BRSV-specific antiserum. Mallipeddi et al. (1990) recendy 
identified and characterized all ten virus-specific polypeptides (Strain A51908) 
ranging in molecular weight from approximately 200 to IIK (Table 2). Viral 
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polypeptides were detected as early as 30 min postinfection and their synthesis 
reached a plateau 12h after infection. The P. protein was highly phosphorylated and 
G, F were glycosylated. N, P, and M were found to be the major polypeptides in 
cells infected by the virus. 
Table 2. Molecular weights of viral-induced proteins in BRSV infected cells 
Polypeptide Molecular weight 
(Kd) 
Post-translational 
Modification 
L 200 -
G 85-100 Glycosylated 
F 68 Glycosylated 
-F, 48 Glycosylated 
-F^ 20 Glycosylated 
N 42 -
P 34 Phosphorylated 
M 29 -
23K 23 -
15K 15 -
13.5K 13 -
IIK 11 -
Source: Mallipeddi et al., 1990. 
Subgroups: Comprehensive studies of the HRSV isolates using monoclonal 
antibodies, polyclonal antibodies, immunizing experiments in cotton rats, and 
monitoring the immune response following natural infection in infants and children 
have delineated at least two antigenic variants designated as subgroup A and B or 1 
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and 2. The antigenic differences between the subgroups have been found to be more 
pronounced with G protein than other proteins (Mufson et al., 1985; Hendry et al., 
1986, 1988; Johnson et al., 1987). Variation even within the groups has also been 
reported. Recently six subdivisions have been identified for subgroup A and two to 
four groups of antigenic variance have been identified within the subgroup B 
(Akerlind et al., 1988; Anderson et al., 1991). Although both subgroups are 
reported to cocirculate during respiratory oudireaks, their prevalence varies both 
during outbreaks and from outbreak to outbreak, but subgroup A generally prevails 
(Hendry et al., 1986a; Mufson et al., 1988; Russi et al., 1989). However a recent 
report regarding subgroup analysis of 613 specimens from Vancouver, Canada 
revealed that from 1987-1992 viruses of subgroup A prevailed (60% to 80% of 
isolates) except during 1988-1989 when subgroup B viruses represented up to 94% of 
the isolates (Thomas et al., 1994). Respiratory disease caused by viruses of each 
group seems not to differ clinically (Heilman, 1990). 
Until recently, BRSV was considered to be a monotypic virus because there have 
been limited attempts to determine the occurrence of antigenic variation among BRSV 
strains. The G protein of BRSV has been reported to possess major antigenic 
differences from the HRSV G protein by immunoprecipitation and western blot 
analysis; however the F, N, M and P proteins of BRSV had antigenic cross-reactivity 
Avith their HRSV counterparts (Lerch et al., 1989). Furthermore, the G protein of 
BRSV was recognized only by a polyclonal antiserum against the homologous BRSV 
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strain (391-2). The inability of the polyclonal antiserum raised against BRSV strain 
127 to recognize the G protein of BRSV strain 391-2 indicated that BRSV has 
antigenic subgroups like HRSV (Lerch, et al., 1989). Baker et al. (1992) studied the 
proteins of HRSV and BRSV in detail and reported major variations in the molecular 
sizes of the P and F proteins of nine BRSV isolates. The SBAH, MN, and 375 
strains had a P protein of smaller molecular size (36Kd) than the other six strains 
which expressed a 38Kd P protein. They further reported the molecular size of FQ, 
F,, and F2 as 68, 48, and 21 Kd for SBAH strain and 63, 47, and 17 Kd for the 
remaining BRSV strains respectively. Based on their findings they raised a question 
about the efficacy of strains used to prepare current BRSV vaccines in the United 
States and also speculated that the vaccine failures may be due to the antigenic 
differences among BRSV isolates. 
Viral target antigens: Commercial and experimental BRSV vaccines have been 
studied for efficacy in stimulating antibody as well as cell-mediated responses. There 
is a single report where immunoaffinity purified F protein of BRSV has been used for 
inducing an immune response (Nelson et al., 1992). These authors concluded that 
seronegative calves responded to primary vaccination with immunoaffinity purified F 
protein by producing neutralizing antibodies. However, subsequent vaccination did 
not increase the antibody response which suggested that the already existing immunity 
suppressed local and systemic neutralizing antibody responses. 
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Almost all of the viral proteins of HRSV, including structural and non-structural, 
have been studied for their role in providing protection against infection in 
experimental animals. In a variety of immunization experiments the F and G proteins 
have been found to provide resistance against HRSV experimental infections; this 
indicates that these glycoproteins are most probably the major independent protective 
antigens (Mcintosh and Chanock, 1990). Viral proteins used in such experiments 
have either been immunopurified or expressed in vaccinia virus. 
Passive transfer of monoclonal antibodies raised against F and G proteins 
significandy reduced or completely prevented replication of HRSV in the lower 
respiratory tract of mice and cotton rats (Walsh et al., 1983). Walsh et al. (1987) 
reported that cotton rats immunized with purified G or F protein (reduced or 
nonreduced) developed complete pulmonary resistance to HRSV challenge. 
However, the nasal passages were only partially protected. The animals immunized 
with either reduced or nonreduced F protein developed neutralizing as well as fusion 
inhibiting antibodies. G protein induced only neutralizing antibodies. 
Levine et al. (1989) evaluated a lyophilized subunit vaccine containing F, G, and 
M proteins in SJL mice. A single dose of this vaccine (50 jug) induced antibodies to 
G which lacked neutralizing activity. Mice given two doses of the same vaccine (50 
jug and 25 /tg) produced antibodies to all of the three proteins and the antisera 
possessed neutralizing activity for RSV. All the vaccinates were protected from 
intranasal challenge. 
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Nicholas et al. (1990) and Openshaw et al. (1990) reported that cytotoxic T 
lymphocyte (CTL) recognition of cells expressing only 22-Kd protein of RSV was 
comparable to CTL recognition of virus-infected cells. The recognition of F and N 
protein was comparatively less. This prompted Nicholas et al. (1991) to explore the 
role of 22-Kd protein in the anti-RSV immune response and its role in providing 
protection against RSV infections. They utilized recombinant vaccinia viruses 
expressing the F protein (Vac-F), FG (Vac-FG), consisting of extracellular domains 
of both F and G), or 22-Kd (Vac-22Kd) protein, for their ability to induce humoral, 
CTL responses and protection in BALB/c mice against A and B subgroups of RSV. 
Immunization with Vac-F induced very high titers of RSV-specific antibodies in all of 
the mice. Inununization with Vac-FG also induced a high titer of RSV-specific 
antibodies, but the titer was substantially lower than that induced by Vac-F. 
Immunization with Vac-22-Kd did not induce any detectable antibody to RSV in 88% 
of the vaccinates. The remaining 12% developed very low titers, which overlapped 
with the negative control values. Vac-F and Vac-FG also induced significant levels 
of cytolytic activity for RSV-uifected cells and provided full protection against 
challenge with viruses of either subgroup of RSV. Immunization with Vac-22Kd 
induced particularly high levels of cytolytic activity for RSV-infected cells and 
provided significant protection against both subgroups of RSV. Based on their 
findings Nicholas et al. (1991) proposed that, in vivo, 22- kd-specific CTL can 
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provide at least partial resistance to RSV replication within the lung in the absence of 
a significant humoral component. 
The N protein has been identified in several studies as a minor protective antigen. 
It probably plays a role in protective immunity through its participation in inducing 
CTL responses ^clntosh and Chanock, 1990). King et al. (1987) reported that N 
protein expressed in vaccina virus afforded a significant degree of protection in 
BALB/c mice. Although vaccination with the recombinant virus expressing N protein 
resulted in a significant reduction in titers in the lungs of mice following live-virus 
challenge, this protection was not as solid as provided by F and G proteins expressed 
and used similarly (Stott et al., 1986, Wertz et al., 1987). Similarly, rats vaccinated 
with a vaccinia recombinant virus that expressed the N protein were not as well 
protected as those immunized with vaccinia recombinants expressing F or G proteins 
(Kimman and Westenbrink, 1990). Bangham et al. (1986) has demonstrated that the 
N protein is one of the target antigens for CTL in man and mouse. Connors et al. 
(1991) have reported that viral proteins F, G, M2 (22-Kd), and N expressed in 
vaccinia virus provide protection to BALB/mice against RSV challenge, but the 
protection induced by M2 and N is comparatively short-lived. They monitored the 
resistance by challenging the mice i/n with RSV on days 9 or 28 postvaccination. 
The F and G proteins provided complete protection on both days. M2 and N induced 
significant but not complete resistance on day 9, but little protection by day 28. 
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Immunization with other viral proteins, also expressed in vaccinia virus, including P, 
SH (1 A), M, IB, and IC did not induce detectable resistance to RSV challenge. 
Tnidel et al. (1989) have indicated that immunostimulating complexes (ISCOMS) 
made from F and N proteins of RSV induce neutralizing antibodies in guinea pigs. 
Similarly BALB/c mice have been reported to be protected from live virus challenge 
by ISCOMs, composed primarily of F, N and, to a lesser extent, G proteins (Trudel 
et al., 1991). Peretz et al. (1992) reported that immunopurified F, G, but not N 
protein induced protection in BALB/c mice. The N protein did not block challenge 
infection but F and G caused a 30 fold reduction of virus titer in lung tissue. In a 
very comprehensive study Connors et al. (1992) demonstrated that antibodies induced 
by F and G proteins, expressed in vaccinia virus, were alone sufficient to provide 
protection to BALB/c mice, because depletion of T cells or interferon did not affect 
their high level of resistance to RSV challenge. However the resistance induced by 
M2 protein, also expressed in vaccinia virus, was mediated primarily by CDB"^ T 
cells. The resistance induced by Vac-M2 was completely abrogated by depletion of 
CDS^ T cells, whereas depletion of CD4^ T cells or interferon had an intermediate 
effect on resistance to challenge. Similar findings have been reported by Kulkami et 
al. (1993). Their results indicated that significant resistance could only be induced 
by Vac-M2 in BALB/c (H-2"' haplotype) and not in BALB.K (H-2'') or BALB.B (H-
2'') mice. This resistance was mainly mediated by pulmonary CTLs and that 
resistance waned to very low level in two months following immunization. A 
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suq)rising observation in their study was that none of the other RSV proteins studied, 
including P, N, M, 1C,1B, and SH (lA), induced significant resistance in these three 
haplotypes of mice. 
In a limited study, Stopner et al. (1993) investigated pairs of acute and 
convalescent sera, obtained from young children aged 1 month to 1 year with acute 
RSV infection, for antibody levels to the C-terminal peptide of SH (lA) protein. The 
antibody levels to the C-terminal were low suggesting that the SH protein was a weak 
stimulant of antibody production in children with natural infection. Recentiy Walsh 
(1993) has documented that inclusion of cholera toxin (CT) with immunopurified F 
protein enhances the resistance of Swiss mice to RSV challenge. 
Diagnosis 
The diagnosis of BRSV is challenging and can be made by several methods 
including virus isolation, immunofluorescence and serology. Virus isolation can be 
made from nasopharyngeal swabs, lacrimal discharges, tracheal washes and lung 
lavages. The latter two samples are ideal for isolation purposes (Kimman, 1986). 
Since the virus is labile, it may be inactivated when the sample is frozen at collection 
and thawed in the laboratory (Bohlender et al., 1982). Since multiple passages may 
be required to detect the virus, it is considered to be the least reliable method for 
diagnosis (Baker, 1993). Paccaud and Jacquier (1970) identified BRSV after 32 days 
in culture and Inaba et al. (1972) had to wait for 17 days. However, efficiency of 
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isolation is enhanced if the samples are inoculated onto susceptible cells at the time of 
collection ^ohanty et al., 1976). Similarly, Frey (1982) had greater success in 
isolation by inoculation of cell cultures immediately after sampling. Collection of 
samples from unaffected animals that are in close contact with the clinically sick 
animals may increase the chances of BRSV isolation (Kahrs, 1981). 
Immunohistochemistry has been reported to be the most dependable method for 
positive identification of BRSV in infected tissues (Smith and Collins, 1987; Baker 
and Frey, 1985; Thomas and Stott, 1981). 
The indirect inununofluorescence (lOF) test not only enables a diagnosis to be 
made very rapidly but also the titers by this method have been found to be higher 
than with a complement fixation test (Wellemans, 1977). Anti-BRSV antibodies in 
serum, nasal mucus and organ extracts can be detected rapidly by this method. 
Fluorescent antibody staining of frozen lung tissue or nasal exudate is used in most 
diagnostic laboratories. Immunofluorescence testing gives better results with 
postmortem lung samples than with nasopharyngeal swabs (Thomas and Stott, 1981). 
The most commonly used serological test is the microtitration serum-virus 
neutralization test (Baker, 1993). Caution is required if this test is to be performed 
on calves less than four months of age due to the potential presence of maternally-
derived antibodies and the possibility of infection (Smith et al., 1975; McNulty et al., 
1983). A serological diagnosis is not possible in calves that still have passive 
immunity. A possible approach to overcome this problem is to sample calves 
representing various age groups (Baker, 1993). 
limnunity and Immunization 
Both HRSV and BRSV infections are common in infants and calves respectively 
and can cause severe disease (Stott and Taylor, 1985; Glezen et al., 1981; Harrison 
and Purseil, 1985). Infections in adults tend to result in less severe disease (Baker et 
al., 1986; Hall et al., 1978). Maternally-derived passive immunity does not provide 
complete protection in calves or infants (Baker et al., 1986a, 1986b, 1986; Glezen et 
al., 1981; Lehmkuhl et al., 1979; Rosenquist, 1974). Repeated infections occur in 
humans and catde but the subsequent infections are comparatively less severe than the 
initial infections (Stott and Taylor, 1985; Baker et al., 1986; Glezen et al., 1981; 
Lehmkuhl et al., 1979; Rosenquist, 1974; Baker et al., 1985; Hall et al., 1976; 
Martin, 1983). 
The role of maternal immunity has been a matter of great debate because HRSV 
and BRSV infections can occur in the presence of maternal antibodies. However, 
studies do indicate that, although passively derived maternal immunity does not 
prevent infection with HRSV, it may provide some protection in ameliorating the 
severity of the disease (Glezen et al., 1981; Ogilvie et al., 1981; Hall et al., 1978; 
Lamprecht et al., 1976). Similar findings have been reported in calves. An 
epidemiological study of BRSV demonstrated that, although maternally-derived 
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antibodies did not prevent infection in calves, the incidence and severity of the 
disease were inversely related to the level of specific maternal antibody (Kinunan et 
al., 1988). Recently Belknap et al. (1991) reported that passively-derived antibody 
reduced the severity of the disease when calves were infected at 48 hours of age. 
The precise role of immunity in RSV infections is not well understood. It has 
also been proposed that immunopathological mechanisms might play a role in RSV 
infections. This theory is speculative, since, if immunopathologic mechanisms are 
important in RSV disease pathogenesis, these need to be clearly defined (Baker and 
Velicer, 1991). It appears that serum antibody is perhaps the major mediator of 
immunity to natural infection with RSV. Cell-mediated immunity appears to be 
important in recovery from RSV infection because viral shedding persists for 
prolonged periods in individuals with a defect in cell-mediated immunity. However 
there is no evidence that the cell-mediated immunity plays any role in prevention of 
infection (Tristram and Welliver, 1993). 
Currendy there are no vaccines available in the United States to control the 
disease in humans, and efforts to develop a vaccine to protect infiants and young 
children have thus fiar failed (Baker and Velicer, 1991). However both live and 
inactivated candidate vaccines for infants and children continue to be tested. In 
contrast, a modified-live virus vaccine for BRSV has been available in Europe since 
1978. In the United States modified-live BRSV vaccines and killed vaccines became 
available in 1984 and 1988 respectively (Baker and Velicer, 1991). There are 
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conflicting reports on the possible effects of live and inactivated vaccination on the 
prevalence of BRSV infections. Several workers have reported that vaccinations 
reduced the prevalence and severity of the disease (Kubota et al., 1992, 1990; 
Howard et al., 1987; Stott et al., 1987, 1984; Morter and Amstutz, 1986; Thomas et 
al., 1986; Frennet et al., 1984) while others found no significant effect (Morisse et 
al., 1990; Ploeger et al., 1986; Holzhauer and Wertenbroek, 1979). A major 
limitation of these vaccines is that maternally-derived antibody to BRSV suppresses 
an active immune response in calves (Kimman et al., 1987; Westenbrink et al., 
1989). Not only the humoral response but also the mucosal antibody response is 
suppressed; however, immunization via the respiratory tract did prime calves, having 
maternal immunity, for memory responses (Kimman et al., 1989; Kimman et al., 
1987; Westenbrink et al., 1989). Thus it is imperative that RSV vaccines should 
have the ability to induce immunity or at least prime the subject in the presence of 
passive immunity because of the early age distribution of severe disease associated 
with RSV. 
Solid Matrix-Antibody-Antigen Complexes 
Antibody-antigen complexes are known to enhance the immune response and have 
been used for the induction of both humoral and cell mediated immune responses 
(Chang et al., 1985). Monoclonal antibodies (MAbs) can be attached to particulate 
solid matrices, and the solid matrix-antibody complexes can be used to purify the 
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required antigen. The resulting complexes, solid matiix-antibody-antigen complexes 
(SMAA), can be used as immunogens. 
Most of the research work involving SMAA complexes as immunogen has been 
undertaken by Randall and his associates, mentioned below. The solid matrix they 
used for most experiments in experimental animals was a "fixed" and killed 
suspension of the Cowan A strain of Staphylococcus aureus. 
A major advantage of designing solid matrix-antibody-antigen (SMAA) complexes 
as vaccines is in the preparation of the immunogen. Many other methods being 
developed to present antigens to the immune system first require the purification of 
the protein of interest, which often involves strong denaturing conditions that may 
irreversibly alter some antigenic determinants. To produce SMAA complexes a 
simple procedure of antigen purification can be used. Also, because the resulting 
SMAA complexes are used as the immunogen, there is no need to use strong 
denaturing conditions to remove the antigen fi'om the complex. These complexes are 
non-infectious, and therefore there is no need to inactivate them using formaldehyde 
or heat. These procedures are commonly used in the production of whole killed virus 
vaccines and can selectively denature particular antigenic determinants and adversely 
affect the induction of a protective immune response. SMAA complexes are also 
relatively stable to prolonged storage conditions, a property that may be advantageous 
in developing countries where it may be difficult to store some vaccines (Randall, 
1989). 
35 
SMAA complexes have been used, by incoiporating in them either internal or 
external proteins from the same virus or from different viruses, for immunization as 
well as determining the humoral and cytotoxic T cell immune responses. Prior 
immunization of mice with SMAA complexes containing either surface or internal 
structural proteins of simian virus 5 (SV5) reduced the amount of virus replication 
within infected lungs; tlie greatest degree of protection was induced by nucleoprotein 
or matrix protein (Randall et al., 1988). In another study Randall and Young (1988) 
observed that immunization with SMAA complexes, containing internal or external 
structural proteins of SV5 without an adjuvant, induced higher levels of antibody than 
the antigen alone precipitated on alum. Further analysis of the cytotoxic T cell 
responses of immunized animals indicated that both surface and internal structural 
proteins can act as target antigens. Randall and Young (1991) further demonstrated 
that immunization with SMAA complexes can induce class 1 restricted cytotoxic T 
cells (CTLs). 
SMAA complexes have also been constructed to produce multivalent immunogens 
containing various virus glycoproteins known to be involved in inducing protective 
immunity. Such complexes, containing glycoproteins of herpes simplex, HA protein 
of influenza and measles viruses, and HN protein of SV5 and parainfluenza virus 
type 2, induced powerful responses in mice. Serum analysis revealed high titers of 
antibodies to all of these viruses (Randall and Young, 1989). 
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In developing vaccines to counter viral infections like HRSV and BRSV, it is 
imperative to produce vaccines that engender the type of immune response best suited 
to provide protection and avoid immunopathology. Thus viral vaccines which, in 
addition to inducing neutralizing antibodies, can also play an important role in 
regulating T cell responses may fulfill these requirements. 
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INTRACYTOPLASMIC MATURATION AND BRIDGE FORMATION OF 
BOVINE RESPIRATORY SYNCYTIAL VIRUS STRAIN 375 IN 
VERO CELLS 
Manuscript prepared for publication in Archives of Virology 
Muhammad Zuliiqar, John J. Andrews, Merlin L. Kaeberle, 
Kenneth B. Piatt, Jean A. Olsen, Howard D. Lehmkuhl 
Microbiology, Immunology, and Preventive Medicine, 
Iowa State University, Ames, lA, U.S.A. 
Summary. In the present study the morphology of bovine respiratory syncytial virus 
(BRSV strain 375) was observed in Vero cells at a stage when extensive cytopathic 
effects were present. 
Electron microscopic examination of ultrathin sections of BRSV-infected Vero 
cells revealed not only spherical and filamentous forms of the virus but also bridges 
between the spherical particles. The length of bridges was 13.1 ± 1.6 nm from the 
outer surface of one particle to the other particle. The bridges did not appear to be 
arranged at a particular angle. Because of the bridges the virus particles occurred in 
large aggregates requiring that this factor be taken into account while purifying the 
virus. The diameter of filamentous forms was uniform but their length varied. Both 
forms were observed budding from the cell membrane of infected cells. Most of the 
observed mature particles were extracellular. However a few spherical particles with 
and without internal structure were also present in intracytoplasmic vesicles. This 
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confinns an earlier report on assembly of virus particles intracellularly in Vero cells 
infected by a member of the family Paramyxoviridae. 
DrmODUCTION 
The genus Pneumovirus of the &mily Paramyxoviridae and sub&mily 
pneumovirinae currently contains human respiratory syncytial virus (HRSV), bovine 
respiratory syncytial virus (BRSV), ovine respiratory syncytial virus (ORSV), caprine 
respiratory syncytial virus (CRSV), pneumovirus of mice and turkey rhinotracheitis 
virus [5]. The members of the family are pleomorphic in structure, have an envelope 
derived from the host cell cytoplasm, and they mature by budding from the plasma 
membrane [8]. Virions observed by electron microscopy are either filamentous or 
spherical in appearance [8]. 
The structure of BRSV strain NMK 7 has been described [7]. Observations of 
ultrathin sections revealed spherical particles measuring 80-130 jum in diameter, and 
also filamentous forms of 100-130 [im in diameter of variable length. Belanger et al. 
[2] reported well-defined bridges between BRSV particles (strain A 51908), 
measuring 12 ± 2.7 nm. A prominent feature of these bridges was their 
arrangement at a 60° angle. No such bridges were reported in strain NMK 7 by Ito 
et al. [7]. Until recently BRSV was considered to be a monotypic virus since there 
had been limited attempts to determine the antigenic variation among BRSV strains. 
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However, very recent studies indicate diat like HRSV, BRSV may also be divided 
into two antigenic groups [1, Furthermore, the hallmark characteristic of the 
members of the Paramyxoviridae femily is independent assembly of their 
nucleocapsid within the cytoplasm and release of the enveloped viruses by budding 
through the plasma membrane [12]. But recently, Moussa [13] reported 
intracytoplasmic maturation of a strain of BRSV. In the present investigation, BRSV 
strain 375, originally isolated from nasal secretions of a calf [9], was observed by 
electron microscopy in ultrathin sections of infected Vero cell cultures. The present 
investigation provided additional evidence of intracytoplasmic maturation of BRSV 
and the presence of bridges between mature virions. 
MATERIALS AND METHODS 
Cells 
Vero cells (Veterinary Diagnostic Laboratory, College of Veterinary Medicine, 
ISU., CRL 1587 Vero 76 from the American Tissue Culture Collection) were 
maintained on Dulbecco's Modified Eagles's Medium [(DMEM), Sigma Chemical 
Company, St. Louis] supplemented with 10% betapropiolactone-treated fetal calf 
serum (Sigma) and 50 /tg/ml of gentamicin (Schering Corporation, Kenilworth, NJ). 
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Propagation of Virus 
Vero cells grown in 175 cm^ tissue culture flasks (Costar Corporation, 
Cambridge, MA) were inoculated with BRSV strain 375 when the monolayer was 
subconfluent and incubated in a humidified chamber with 5 % CO2 at 37°C. A low 
titer of virus i.e., 10^/ml was obtained up to day 3 to 4 postinfection. Modification 
of the culture procedure resulted in a methodology that routinely yielded a titer of 
10®-Vml. 
Cells were infected with virus (2xlOVml) when the monolayer was about 80% 
complete. When viral cytopathic effect (CPE) was initially observed, usually 44-50h 
postinfection, the cells were trypsinized and transferred with an equal quantity of 
trypsinized uninfected Vero cells to a 225 cm^ flask (Coming Incorporated, Coming, 
NY). On further incubation (24-48h), 90-100 % CPE was present and the cells were 
harvested for electron microscopy. 
Immunofluorescent Assay 
Infected and uninfected Vero cells (2x10^ cells/well) were grown on teflon coated 
slides (ICN Biomedicals, Aurora, Ohio). When CPE was distinct, the cells were 
fixed in 80% acetone at room temperature and stored at -20°C. A monoclonal 
antibody (MAb) raised against BRSV (courtesy Professor Dr. Kenneth B. Piatt, 
MIPM, ISU) or negative supernatant from SP2/0 cells were added to the wells. 
Bound antibody was detected by probing with fluorescein isothiocyanate (FTTC)-
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labeled anti-mouse IgG [Kirkegaard & Perry Laboratories, Inc. (KPL), Gaithersburg, 
MD] dUuted 1:40 in PBS. Processed slides were examined under ultraviolet Ught for 
fluorescence. 
Electron Microscopy 
Cells were harvested when extensive CPE had developed. The medium was 
discarded and the monolayer was washed with phosphate buffered saline (PBS, pH 
7.2) followed by the addition of 3% glutaraldehyde solution in 0.1 M cacodylate 
buffer (pH 7.2). The cells were fixed for ten min, removed from the flask sur&ce 
with a cell scraper, and centrifuged at 1500 G for ten min. Uninfected Vero cells 
were prepared by the same method. Cell pellets were resuspended in 3 % 
glutaraldehyde for two hours at 4''C. The cells were subsequently washed in the 0.1 
M cacodylate buffer three times, post-fixed with 1% osmium tetroxide in 0.1 M 
cacodylate buffer for two hours, dehydrated in a graded acetone series, and 
embedded in epoxy resin (Embed 812, Electron Microscopy Science, Fort 
Washington, PA). Ultrathin sections were cut on an LKB ultramicrotome, stained 
with 2% uranyl acetate and Reylond's lead citrate and examined with a Hitachi H500 
transmission electron microscope. 
Electron micrographs were taken on Kodak Electron Microscope Film 4489 
(Eastman Kodak Company, NY) using a two second exposure time. The film was 
developed in Kodak D-19 developer diluted 1:2 with distilled water for four min at 
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68°F. Prints were made using a Durst Labrator 138-S enlarger with a point light 
source. The paper used for this puipose was either Kodabromide grade 4 or 5 or 
Kodak Polycontrast ni RC with Kodak Poly contrast filter number 4 or 5. It was 
developed 1-2 min in Kodak Dektol Developer diluted 1:2 with distilled water, fixed 
in Kodak fixer and dried with an Omega/Akray DualDri model ISO print dryer. 
RESULTS 
Light Microscopy 
The extensive cytopathogenic changes induced by BRSV are illustrated in Fig. 1. 
Large syncytia containing over 30-50 cells were generally seen. 
Immunofluorescence Assay 
The presence of the BRSV in the infected cells was demonstrated by indirect 
immunofluorescence assay. Infected cells stained with indirect immunofluorescence 
method using a MAb specific for BRSV and FTTC labeled anti-mouse IgG 
demonstrated typical diffuse bright apple green color (Fig. 2). Uninfected cells failed 
to fluoresce. 
Electron Microscopy 
In the ultra thin sections of the virus-infected Vero cells, maturation of virus 
particles was observed at the cytoplasmic membrane (Fig. 3). Five to seven dots, 
Figure 1. Vero cells infected with BRSV. Large unstained syncytia can be seen all 
over the microscopic field. X250 
Figure 2. BRSV antigen in acetone fixed infected Vero cells stained by indirect 
fluorescent antibody technique. X400 
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representing the nucleocapsid, appear beneath the membrane of individual virus 
particles half way through their budding-off process. The virus particles displayed 
pleomorphism with spherical particles measuring 102.4 ± 7.8 nm in diameter (Fig. 
4,5) and filamentous forms 74-109 nm in diameter and of variable length. 
Both filamentous and spherical particles were either empty or contained electron 
dense internal components. The filamentous as well as spherical forms without inner 
structure outnumbered the forms having internal structure. Two parallel strands with 
a diameter of 7-10 nm were detected in the core of some filaments (Fig. 5). The 
nucleocapsid of many spherical particles was represented by 'dots' numbering 10-12 
per particle (Fig. 4). Some particles had fewer dots. The dots were found to be of 
very uniform size and their diameter was 15.1 ± 0.8 nm. 
Well defined structures forming bridges between spherical particles were 
regularly seen. Their length was 13.1 ± 1.6 nm (Fig. 5) from the outer surface of 
one particle to the other particle. In some cases they appeared as sharply defined 
structures (Fig. 5) but in others they appeared somewhat fiizzy in appearance or 
occasionally as an electron-dense condensed mass between spherical particles (Fig. 
4). Most of these bridges consisted of 2 parallel dense lines and their diameter was 
13.2 + 1.4 nm depending on the number of lines making a bridge. In case of fiizzy 
appearing bridges the diameter appeared larger but it was difficult to determine the 
number of dense lines making the bridge (Fig. 4). The bridges did not appear to be 
Figure 3. Two stages of the budding-off process of BRSV from the cytoplasmic 
membrane of a Vero cell. Note the presence of symmetrically arranged 
dots (nucleocapsid) at the place of budding. Bar marker represents 200 
nm. 
Figure 4. Left; Spherical virus particles showing bridges (b) and dots (d). Note 
some bridges are attached to only one particle (arrow). Bar marker 
represents 200 nm; Right: Same field at higher magnification. 

Figure 5. Upper: Spherical virus particles with and without internal structures. 
The bridges do not appear to be at a particular angle. Filamentous (f) 
form shows two parallel strands. Bar marker represents 200 nm. 
Bottom: Same field at higher magnification showing detailed structures; 
b, bridges; bm, bilayer membrane; d, dots; f, filament. Bar marker 
represents 100 nm. 
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ananged at a particular angle. Some bridges which had only one end attached to a 
virus particle were also observed (Fig. 4). . 
Although the majority of virus particles appeared to mature at the cell sur&ce, 
there were some indications of intracytoplasmic maturation. Mature spherical virus 
particles contained in a vesicle (Fig. 6) were observed. Inclusions containing thread­
like material (nucleocapsid) were located in the cytoplasm. Empty membranous 
vacuoles (Fig. 7) of various sizes and forms were present in the matrix of the 
inclusion. A few spherical virus-like particles were observed within and at the 
periphery of the inclusions (Fig. 8). 
DISCUSSION 
The BRSV strain 375 infected Vero cells were primarily processed for confirming 
the presence of the virus in the infected cells. During this processing some of the 
interesting features of BRSV strain 375 were observed, which have not been reported 
previously. Thus it seemed appropriate to report our findings. These observations 
confirmed the reports of intracytoplasmic maturation and bridge formation between 
virus particles. In the present study the morphology of BRSV strain 375 was only 
observed in cultures showing extensive CPE. Our findings with respect to 
morphology are in general agreement with those of others [2, 7, 16]. However, the 
size of bridges as well as that of 'dots' of strain 375 were slightly larger than that of 
Figure 6. An intracytoplasmic vesicle (v) showing four spherical (s) virus particles 
with and without internal structure. Bar marker represents 200 nm. 
Figure 7. A large inclusion (I) showing membrane limited vacuoles (v) of variable 
size. Bar marker represents 400 nm. 
Figure 8. An inclusion (I) showing spherical virus like particles (sv). Bar marker 
represents 500 nm. 

53 
strain A 51908. This difference in size could be due to cells or electron microscope 
used in this study. Filamentous and spherical particles without inner structure 
outnumbered the filaments as well as spherical particles having internal structure 
[14]. Probably only the latter are infectious; thus the consistently observed 
predominance of apparently incomplete virus might account for the generally low 
order of infectivity encountered with the RS viruses [7, 10, 11]. 
Well defined bridges between spherical particles were regularly observed. 
However they did not appear to be at a particular angle as reported by Belanger et al. 
[2]. Such bridges have not been reported for the Long sttain of human respiratory 
syncytial virus or the NMK 7 strain of BRSV [2, 3,7]. The available literature 
supports the view that these bridges are strain dependent [2] but their biological 
significance and origin are not currendy known. The length of the bridges did not 
appear to exceed that of two spikes measured end to end, which gives rise to a 
possibility that these may be some form of viral spikes (condensed viral spikes), but 
the viral spikes in our study itself were not well defined. At least in one case the two 
bridges between two particles were not of the same size (Fig. 5), because of their 
position on the virus particles. So far no bridges or other regular structure 
connecting the filamentous forms have been reported. Belanger et al. [2] suggested 
that the high frequency of the presence of bridges in cross sections of virus particles 
indicate a longitudinal arrangement along filamentous forms. This was corroborated 
by observations of parallel and equidistant filamentous particles in longitudinal 
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sections; the space between filamentous fonns appeared slightly electron-dense with 
occasional condensation of more electron-dense material. Most of the bridges 
observed by us are very discrete and do not appear to be the electron dense material 
in cross section. If the spherical particles are cross sections of filamentous forms 
[14] then some sort of connection between filamentous forms should be discernible. 
Another view could be that bridges are independent structures coded by the viral 
genome [2]. 
The BRSV strain 375 induced massive syncytia in Vero cells. Virus particles 
were seen budding from the plasma membrane and also lying outside or on the 
plasma membrane. However, spherical virus particles contained in vesicles were 
observed in the cytoplasm, which supports the findings of Moussa [13] regarding 
intracytoplasmic maturation of a BRSV strain. The difficulty experienced in 
achieving a high titer of BRSV in cell culture could also be partly due to 
intracytoplasmic maturation. We have observed that to produce a high titer of BRSV 
strain 375, 4-6 continuous passages are required in Vero cells (unpublished report). 
As such there is a possibility that with passage the overall population of Vero cells 
becomes conducive for viral replication while a minor subpopulation may have a 
restrictive effect leading to intracytoplasmic maturation. Abortive replication of 
influenza virus in nonpermissive HeLa cells has been reported. This restriction does 
not occur early in the virus growth cycle, but appears to be a defect in a late event 
resulting in large intracytoplasmic vesicles filled with budding particles [4], 
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Similarly, restriction on influenza virus can be imposed in permissive cells by 
treating the cells with concanavalin A [15].. Therefore intracytoplasmic maturation in 
Vero cells may be a host restricted factor rather than a character of the BRSV strains. 
Further studies are indicated, using different cell lines to minimize the host cell 
related variations to arrive at some final conclusion regarding the intracytoplasmic 
maturation of different strains of BRSV. 
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Summary 
A panel of monoclonal antibodies (MAbs), derived from the iiising of the primed 
BALB/C mice spleenocytes to SP2/0 cells, were generated against the N protein of 
bovine respiratory syncytial virus (BRSV), strain 375. Different methods were used 
to inmiunize the mice for production of hybridomas and eventually MAbs. 
According to the class and subclass of Ig these MAbs can be grouped into four 
groups. 
The MAbs were characterized by ELISA, a radioimmunoprecipitation assay, 
indirect immunofluorescence, and epitope mapping. To characterize these MAbs we 
used an ELISA competitive binding procedure based on the biotin-avidin system and 
enzyme-linked immunosorbent assay. Eight MAbs, two from each group, were used 
for epitope mapping. The competitive binding assay indicated competing and non 
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competing MAbs. The reaction pattern of the MAbs indicated 4 to 6 antigenic sites 
on the N protein. 
Immune complexes consisting of radiolabeled BRSV and newly generated N 
protein MAbs, or radiolabeled BRSV and human respiratory syncytial virus N protein 
MAb were mixed and then electrophoresed together to monitor the electrophoretic 
mobility of the precipitated N proteins. The N proteins moved together indicating 
that they had the same molecular weight (43.4 Kd) and signifying that the generated 
MAbs were against the N protein of BRSV. This apparently is the first report of 
MAbs specific for N protein of BRSV. 
Introduction 
Economic losses due to respiratory disease in the United States catde industry 
range from 250 to 750 million dollars annually.' Bovine respiratory syncytial virus 
(BRSV), an important pathogen of cattle, is considered to be a major contributor to 
the incidence of respiratory tract disease in nursing beef, feed lot and dairy calves.^ '^  
Virus isolation and seroepizootiological studies have demonstrated that exposure of 
cattle to BRSV is widespread in many countries.^ '® ®'' *''-"' 
BRSV is an enveloped, single stranded, negative sense RNA virus that has been 
classified with human respiratory syncytial virus (HRSV) as a Pneumovirus in the 
family Paramyxoviridae." The viruses are antigenically related'^  and cause the 
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greatest morbidity in their respective species during the first six months of life when 
maternal immunity is still present. Reinfections are common and difficulties have 
been encountered in providing protection through live or inactivated vaccines against 
respiratory syncytial viruses (RSV)." A major limitation of these vaccines is that 
maternally derived immunity to BRSV suppresses an active immune response to 
vaccination in calves."'" 
No definitive studies appear to have been published regarding the specificity and 
duration of maternal immunity in calves. However, Westenbrink et al.,*' in a very 
limited study, reported moderate levels of maternal antibody with specificity for the F 
and N proteins in three 2 to 3 wk old calves. Similarly, they observed in 6 to 7 
month old calves, recovering from BRSV-associated disease, development of an 
antibody response, which was directed predominantly to the F and N proteins of the 
virus. Both F and N proteins of HRSV have been extensively used for inducing 
immunity in experimental animals.There appears to be only one report 
whereby immunoaffinity purified F protein of BRSV has been used for inducing 
immunity in calves.^ " This report concluded that seronegative calves responded to the 
primary vaccination with F protein by producing neutralizing antibodies but 
subsequent vaccination did not boost the response, suggesting that already existing 
anti F antibody suppressed the immune response. Neither the production of 
monoclonal antibodies against N protein nor vaccination with N protein of BRSV has 
apparendy been reported. Therefore the objective of the present study was to 
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generate monoclonal antibodies (MAbs) against N protein of BRSV strain 375, 
originally isolated from nasal secretions of a calf,^ ' and to characterize these by 
ELISA, indirect immunofluorescence, radiormmunoprecipitation assay (RlPA), and 
epitope mapping. 
Materials and Methods 
Cells and viruses - Vero cells (Veterinary Diagnostic Laboratory, College of 
Veterinary Medicine, ISU., CRL 1587 Vero 76 American Tissue Culture Collection) 
were maintained on Dulbecco's Modified Eagles's Medium [(DMEM), Sigma 
Chemical Company, St. Louis] supplemented with 10% betapropiolactone-treated 
fetal calf serum (Sigma) and 50 jug/ml of gentamicin (Schering Corporation, 
Kenilworth, NJ). 
Propagation of virus - Vero cells grown in 175 cm  ^tissue culture flasks (Costar 
Corporation, Cambridge, MA) were inoculated with BRSV strain 375 when the 
monolayer was subconfluent and incubated in a humidified chamber with 5 % CQz at 
37°C. A low liter of virus i.e., iC/ml was obtained up to day 3 to 4 postinfection. 
Modification of the culture procedure resulted in a methodology that routinely yielded 
a titer of 10® Vml. 
Cells were infected with virus (2xl0 /^ml) when the monolayer was about 80% 
complete. When viral cytopathic effect (CPE) was initially observed, usually 44-50h 
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post-infection, the cells were trypsinized and transferred with equal quantity of 
trypsinized uninfected Vero cells to a 225 cm  ^ flask ( Coming Incorporated, NY). 
On further incubation (24-48h) 90-100 % CPE was present and the cells were 
harvested to prepare antigen, for immunization of mice and western immunoblot 
assay (WIA). 
Mouse myeloma SP2/0 cells (American Tissue Culture Collection CRL 1581) 
were grown in DMEM supplemented with 7.5% hybridoma serum (Sigma), 200 mM 
L-glutamine and 50 jiig/ml gentamicin sulfate (Schering Corporation, Kenilworth, NJ) 
according to a procedure described by Van Deusen  ^with some modifications. For 
growth of fusion products, first HMT medium (Sigma) and then HT medium (Sigma) 
was used. For preparation of these media DMEM was supplemented with 20% 
hybridoma serum, 20% conditioned medium, 2% HMT or HT (Sigma) along with 
gentamicin and L-glutamine as mentioned above. 
Generation of monoclonal antibodies 
Immunization of mice: Three preparations were used to prime 10-12 week old 
BALB/c mice for generation of MAbs against N protein of BRSV. 
1. Electrophoresed N-protein: BRSV infected cells showing 90-100% CPE were 
centrifuged at 2(XX) g for ten min. The pellet was washed twice in DMEM (serum 
free). After a second washing, lysate buffer (150mM-NaCl, 1 % sodium 
deoxycholate, 1% Triton x-100, 0.1% SDS, lOmM-Tris-HCl pH 7.4) was added at 
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10 X volume of the pellet and stirred overnight at 4°C. The preparation was 
centrifiiged, the supernatant was collected and the protein content determined by the 
BCA protein assay (Bio-Rad Laboratories, Hercules, CA) and adjusted to 4 mg/ml 
with PBS (pH 7.2). This preparation was boiled at 100°C for five minutes with an 
equal volume of sample buffer consisting of 2% SDS, 50% glycerol and 0.05% 
bromophenol blue in 0.5M Tris buffer (pH 6.8). This viral antigen (100 ul) was run 
through 10% SDS-PAGE  ^to resolve viral proteins. To locate the layout of the 43K 
Mr protein band gel strips (0.5 cm wide) were cut out from each side and stained 
with 0.1 % Coomassie blue (Sigma). After destaining, both the cut out gel strips 
were placed in water to rehydrate and then placed back in their original position. 
The portion of unstained gel corresponding to the stained 43K M, protein band was 
removed and stored at -70°C for further use. The band was freeze-thawed twice and 
ground to make a syringeable suspension in PBS. This suspension was inoculated 
intraperitoneally (i/p) into a group of mice. Three injections (Table 1) were given 
three weeks apart. Four days before fusion, the mice were injected i/p with 1x10' 
BRSV infected cells. 
2. BRSV infected cells: Another group of mice was inoculated i/p with whole 
BRSV infected cells (1x10' cells/mice) as described by Klucas and Anderson.^  A 
booster dose was administered three weeks following primary immunization (Table 
1). Four days before fusion, the mice were boosted with another dose of BRSV 
infected cells (1 x 10' cells). 
64 
Table 1. Lnmunization of mice for generation of monoclonal antibodies. 
Type of immunogen Weeks Dose Adjuvant 
Electrophoresed N protein 0 2-3 Mg No 
3 2-3 Mg No 
6 2-3/*g No 
N protein dissociated from 0 6-8 11% FCA 
immobilon membrane 3 6-8 /tg FIA 
6 6-8 #tg FIA 
9 6-8 ng FIA 
12 6-8 jtig FIA 
BRSV infected Vero cells 0 1x10' cells No 
3 1x10' cells No 
FCA = Freund's complete adjuvant; FIA = Freund's incomplete adjuvant. 
3. N protein dissociated from immobilon membrane: The viral antigen was prepared 
and electrophoresed by SDS-PAGE as previously described. The resolved proteins 
were transferred to an immobilon membrane (Millipore Corporation, Bedford, MA). 
Proteins were stained with 0.1 % amido black (Sigma) and the 43K protein band 
was excised and stored at 4°C. A group of mice was primed with N-protein 
dissociated from immobilon membrane according to a protocol described by 
Szewczyk and Sununers." The dissociated N protein pellet was solubilized in PBS 
and incorporated into an equal volume of Freund's complete (Sigma) adjuvant to 
make water-in-oil emulsion and inoculated i/p into a group of mice. The boosting 
preparations were prepared similarly except that Freund's incomplete adjuvant 
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(Sigma) was used. Five immunizations (Table 1) were carried out at three week 
intervals. Four days before fusion, the mice were boosted vidth BRSV infected cells 
as described previously. 
Fusion: Four days after final injection, cell fusion was performed according to 
the procedure of Van Deusen.^  Hybridomas positive by ELISA and immuno­
fluorescence were cloned by limiting dilution,^  rescreened and further characterized 
by radioimmunoprecipitation and epitope mapping. 
Ascites: To generate ascites fluids containing monoclonal antibodies, mice were 
primed with 0.5 ml of pristane (2,6,10,14-tetramethylpentadecane) (Aldrich Chemical 
Company, Inc., Milwaukee, WI) i/p. Three weeks after priming, mice were 
inoculated i/p with 1x10  ^hybridoma cells, which were washed and resuspended in 
PBS.^  Ascites fluids were drawn 2-3 weeks post inoculation with a myelography 
needle (Becton-Dicldnson, Rutherford, NJ), centrifiiged, and stored at -70°C. 
Isotyping - A mouse isotyping kit (Boehringer Mannheim Corporation, Indianapolis, 
IN) was used according to the procedure recommended by the manufacturer for 
determining the immunoglobulin class and subclass. 
Immunofluorescence assay - Infected and uninfected Vero cells (2x10  ^cells/well) 
were grown on teflon coated slides (ICN Biomedicals, Aurora, Ohio). When the 
CPE was well marked, the cells were fixed in 80% acetone at room temperature and 
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stored at -20°C. Hybridoma supernatant culture fluid was added to the wells, and 
bound antibody was detected by probing with fluorescein isothiocyanate (FTTC)-
labeled goat anti-mouse IgG or IgM [Kirkegaard & Perry Laboratories, Inc. (KPL), 
Gaithersburg, MD] diluted 1:40 in PBS. Processed slides were examined under 
ultraviolet light for fluorescence. 
Radioimmunopredpitation assay - BRSV-infected and Sham-infected Vero cells were 
radiolabeled according to the procedure of Bernstein and Hruska" with some 
modifications. Vero cells were grown in a 75 cm  ^flask and infected with BRSV as 
described previously. Six hours after adding the uninfected cells to infected cells the 
medium was replaced with methionine-fiee MEM (Sigma), incubated at 37°C for one 
hour, and the medium was replaced with fresh methionine-free MEM containing 100 
/itCi/ml ®'S-methionine (ICN Biomedicals, Inc., Irvine, CA). Twenty hours after the 
addition of'®S-methionine, when the CPE was over 80%, the cells were removed 
firom the plastic surface with a scraper, and pelleted by centriiiigation at 300 g for 15 
min. The cell pellet was then disrupted with one ml of RIPA buffer,^  vortexed 
vigorously for one minute and placed on ice for three min. The cellular residue was 
removed by centrifuging at 300 g for 15 min. Mock-infected cell lysate was 
prepared by the same protocol. 
Aliquots (50 fil) of labeled antigen were mixed with 50 ^1 of undiluted hybridoma 
supernatant. Antigen-antibody complexes were precipitated with a 30% suspension of 
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equal volumes of protein A and G Sepharose beads (Sigma), or anti-mouse IgM-
cross-linked beaded agarose (Sigma) according to the isotype of the hybridoma 
supernatant. Similarly N monoclonal antibody (Courtesy Dr. Dan Speelman, 
American Cyanamid Company, West Henrietta, NY) raised against HRSV '^ was used 
at 1:10 dilution for precipitating N protein from BRSV infected Vero cells. The 
precipitated antigen-antibody complexes were subjected to SDS-PAGE on 10% 
polyacrylamide gel.^  The gel was fixed in 7.5% acetic acid in deionized water, 
incubated in autoradiography enhancer (Dupont, NEN Research Products, Boston, 
MA), dried and exposed to X-OMAT film. 
Electrophoretic mobility of N proteins immunoprecipitated by human and 
bovine MAbs: Equal quantities of the immunoprecipitated complexes, prepared for 
RIP A, containing HRSV MAb and BRSV MAb specific for N protein of the 
respective viruses were mixed together. These complexes were subjected to SDS-
PAGE as already described for monitoring the electrophoretic mobility of the N 
proteins precipitated both by human and bovine MAbs. 
Enzyme-Linked Immunosorbent Assay 
Preparation of antigens for ELISA: Cell and viral antigens were prepared 
according to the method described by Bruckova et al.^ ° Both viral (+ag) and control 
(-ag) antigens were diluted to 10 jitg/ml in PBS containing 0.05 % sodium azide 
(PBSN). This preparation was used for coating the ELISA plates. 
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ELISA procedure: Immulon 4 microplates (Dynatech Laboratories, Inc., 
Chantilly, VA) were coated with 50 jul of PBSN (10 /xg/ml ag) and incubated in a 
sealed zip-lock bag overnight at room temperature. Each plate contained alternate 
rows of +ag and -ag. Following the overnight incubation, the plates were stored at 
4°C for no more than four months in a sealed container. Indirect ELISA as described 
by Coligan et al.^  was performed. Hybridoma culture supematants diluted 1:5 were 
used as primary antibody. Peroxidase-labeled goat anti-mouse IgG (H+L) (KPL) 
(1:500) was used as secondary antibody. ABTS peroxidase substrate (KPL) was used 
for development of color and 1 % SDS was used to stop the reaction. Absorbance 
values were determined with a kinetic microplate reader (Molecular Devices 
Corporation, Menlo Park, CA) with a test filter wavelength of 405 nm. 
Epitope mapping: Eight monoclonal antibodies, two from each group, were 
processed for epitope mapping according to the procedures described 
previously '^""''®''^  with some modification as mentioned below. 
The protein concentration of the precipitated antibodies was adjusted to 1.5 
mg/ml with 0.1 M Na HCO3 buffer. For the purpose of biotinylation 1.0 mg of 
biotinamidocaproate N-hydroxysuccinimide ester (Sigma) was dissolved in 1.0 ml of 
dimethyl sulfoxide (Sigma). One hundred jul of it was immediately added /ml of the 
MAb and allowed to react for 2h at room temperature with periodic mixing. 
For competitive ELISA both the labeled and unlabeled MAbs were diluted 1:2 
with glycerol. The ELISA procedure was essentially the same as already described 
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with the following changes. Plates were coated with 100 nl of +ag (30 ng/ivl) in 
coating buffer (O.OIM sodium borate, pH 9^2) and incubated at 4°C for 18h. The 
optimum dilution of the biotinylated MAbs was determined by diluting 1:10 to 
1:10,240 in blocking buffer (0.01 M sodium borate with 2% BSA) and analyzed with 
no competing MAbs. Since a 1:100 dilution at the rate of 1(X) ^1/well gave a 
consistent OD value of one, the biotinylated MAbs were used at this dilution in the 
competitive ELISA. Two procedures were used for monitoring the competition. In 
the first procedure, the unlabeled MAbs (75 /tl/well) in four different concentrations 
(1:25 to 1:100) were incubated at room temperature for 18h. Without aspirating the 
wells, 25 /il of biotinylated MAbs were added and the plate incubated at 37°C for two 
hours.In the second procedure, the biotinylated and four different concentrations 
(1:25 to 1:100) of unlabeled MAbs were incubated simultaneously (50 ul each/well) 
and the plate incubated at 37°C for two hours.^  ^ After washing the plates, 100 ul of 
streptavidin peroxidase (KPL) diluted to 1:4000 in PBS with 1 % BSA was added to 
each well and the plates incubated at 37°C for one hour. The plates were washed and 
iurther processed as described earlier. The percentage of competition was calculated 
according to the formula: (l-A/A^uu  ^100, where A is the mean of the specific 
absorbance of wells with the competing MAbs, and A^  ^is the mean of the specific 
absorbance for wells with diluent in place of competing MAbs. The competition was 
considered significant when the inhibition was 50% or more. 
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Results 
Immune response - A panel of hybridoma cell lines secreting MAbs specific for N 
protein of BRSV were generated employing three different procedures. The MAbs 
generated in this study could be grouped into four groups (Table 2) according to Ig 
class and subclass. 
Table 2. Grouping of MAbs according to Ig class and subclass 
Antibody class 
Group and subclass Designation of MAbs 
A IgM, K 61-1, 61-7, 61-13, 61-19, 65-4, 
65-7, 65-9, 95-10 and 65-11 
B IgM, X 65-12 and 65-16 
C IgG„ fc 25-0, 25-2, 25-3 and 25-7 
D IgGj., #c & X 38-6, 38-7, 38-8 and 38-9 
Group A and group B MAbs were generated from the same fusion, originating 
from two wells 65 and 61. For generation of these MAbs BALB/c mice were primed 
with electrophoresed N protein contained in polyacrylamide gel strips. The 
hybridomas of these wells were cloned, screened and consequendy 11 subclones were 
raised. Most of these subclones produced IgM, K and only two produced IgM, X 
antibodies. Group C and group D MAbs originated from single well 25 and 38 
respectively from separate fusions. These MAbs were generated from BALB/c mice 
primed with BRSV infected cells and N protein disassociated from inmiobilon 
membrane respectively. 
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Characterization of MAhs 
ELISA: Primary and cloned hybridomas giving an OD value of 0.9 or greater 
with viral antigen and O.IS or less with cell antigen were selected for growing for 
collection of supernatant for further studies. 
Lnmunofluorescence: The immunofluorescence pattern we observed with these 
MAbs revealed localized nucleoprotein in the cytoplasm in early infection cycle (Fig. 
1). Neither annular fluorescence nor peripheral filamentous extensions protruding 
from the cell surface, consistent with specificity for a protein expressed on the cell 
surface, were observed, 
Radioimmunoprecipitation assay: The hybridoma supematants were used to 
immunoprecipitate polypeptides from virus-infected and uninfected Vero cells, labeled 
with ^^S-methionine. The immunoprecipitates were analyzed on 10% polyacrylamide 
gel. The pattern of RIPA reactions indicated that all the MAbs precipitated a 43 Kd 
protein from viral infected cells (Fig. 2, 3, 4). None of the MAbs precipitated 
proteins from uninfected cells, suggesting that these MAbs were specific for the 43 
Kd viral protein, which is the N protein. This specificity was confirmed by 
comparison with immunoprecipitation pattern formed by a reference MAb (MAb 
against N protein of Long strain of HRSV.^ ' The reference MAb precipitated a 
protein of identical size (Fig. 2) and, when complexes formed by test and reference 
MABs were mixed, and subjected to electrophoresis a single band of precipitate was 
observed. Both the N proteins precipitated by human and bovine MAbs migrated 
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Figure 1. Intracytoplasmic fluorescence in BRSV infected Vero cells produced by N 
protein monoclonal antibody. The cells were fixed in acetone and air 
dried. Wells were incubat^  with hybridoma supernatant followed by a 
1:40 dilution of fluorescein-labeled anti-mouse IgG antibody. 
Figure 2. Radioimmunoprecipitation of ^^S-methionine-labeled BRSV strain 35 
infected and uninfected Vero cells with D14 (MAb raised against N protein 
of HRSV) and 61-1 (MAB raised against N protein of BRSV). Hybridoma 
supernatant of 61-1 MAb and ascites fluid of MAb D14 diluted 1:10 in PBS 
was used to inimunoprecipitate polypeptides from BRSV infected and 
uninfected Vero cells. *'*C-methylated proteins as molecular weight 
markers. Lane 1 and 3=Uninfected Vero cells precipitated with MAb D,4 
and 61-1 respectively. Lane 2 and 4=Infected Vero cells precipitated with 
D,4 and 61-1 respectively. Antibody-antigen complexes were collected 
with Protein A and G coated Sepharose beads and antimouse IgM-agarose 
respectively. The complexes were subjected to SDS-PAGE on 10% 
polyacrylamide gel. The gel was fixed in acetic acid, dried and exposed 
to X-OMAT fihn. 
Figure 3. Radioimmunoprecipitation of S-methionine-labeled infected and 
uninfected Vero cells with three MAbs (65-12, 65-16 and 38-5) directed 
against N protein of BRSV. Lane 1 = '^*C-methylated proteins as molecular 
weight markers. Lane 2, 4 and 6=Uninfected Vero cells precipitated with 
N protein MAbs of BRSV. Lane 3, 5 and 7=BRSV infected Vero cells 
precipitated with N protein MAbs of BRSV showing 43 Kd precipitated 
protein. Hybridoma supematants were used to inununoprecipitate 
polypeptides from BRSV infected and uninfected Vero cells. Antibody-
antigen complexes were collected with either Protein A and G coated 
Sepharose beads or antimouse IgM-agarose according to the isotype of the 
MAb. Further processing was as mentioned above. Since 38-5 indicated 
some reactivity with viral protein other than N protein, it was discarded. 
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Figure 4. Radioimmunoprecipitation of ^^S-methionine-labeled infected Vero cells 
with seven MAbs directed against N protein of BRSV and one MAb (D14) 
directed against N protein of HRSV. Lane 1 and IO=^^C-methylated 
proteins as markers. The markers were added on both sides to measure 
exactly the molecular weight of N protein by image analysis which, was 
found to be 43.4 Kd. Lane 2=Mab 38-6. Lane 3=MAb 25-2. Lane 
4=MAb 65-12. Lane 5=MAb 61-1. Lane 6=Mab Dj4. Lane 7=MAb 
61-19. Lane 8 =MAb 61-13. Lane 9=MAb 61-7. Hybridoma 
supematants and ascites fluid (D14) were used to immunoprecipitate 
polypeptides from BRSV infected Vero cells. The complexes were 
subjected to SDS-PAGE on 10% polyacrylamide gel. The gel was fixed in 
acetic acid, dried and exposed to X-OMAT film. 
Figure 5. Radioimmunoprecipitated complexes (REPC) precipitated by N protein 
MAbs of BRSV and N protein MAb of HRSV were mixed and subjected 
to SDS-PAGE on 10% polyacrylamide gel. The gel was fixed in 7.5% 
acetic acid, dried and exposed to X-OMAT film. "C-methylated proteins 
as markers. Lane 1 =RIPC precipitated by D,4. Lane 2=]^C 
precipitated with D14 and 38-7. Lane 3=RIPC precipitated with 38-6. 
Lane 4=RIPC precipitated with D14 and 65-16. Lane 5= RIPC 
precipitated with 65-16. Lane 6=RIPC precipitated with D,4 and 61-1. 
Lane 7=RIPC precipitated with 61-1. Lane 8=RIPC with D14 and 25-2. 
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together and did not separate (Fig. S) on electrophoresis, which further confirmed 
that the generated MAbs were specific for the N protein of BRSV. 
Epitope mapping: The two procedures which were used for epitope mapping 
gave somewhat different results. The staggered incubation procedure^^ identified 4 
antigenic sites (A,B,C,and D) on the N protein (Fig. 6). MAbs 25-0, 25-3, 38-7, 
and 38-9 competed over 50% with all other MAbs, signifying that these MAbs bind 
to an identical epitope (Antigenic site A). Although 61-1 and 61-7 appear to bind a 
similar epitope (Antigenic site B) but these two MAbs exhibited a lower competition 
with 25-0 and 25-3. This may be an overlapping epitope or a distinct epitope. 
MAbs 65-12 and 65-16 compete over 50% with 50% and 62% of all the MAbs 
respectively but their reactivity with the remaining MAbs is markedly different, 
suggesting these two interact with independent antigenic sites C and D respectively 
(Table 3). 
The simultaneous incubation procedure'" indicated 6 epitopes (A',B',C',D',E and 
F) CPig- 7) rather than 4 epitopes. In particular, antigenic site D' appears to be 
entirely different from the other antigenic sites. MAb 38-9 exhibited far less 
competition with all other MAbs (Table 4). This could be due to the epitope itself, 
or the binding of MAbs may have altered the site to such an extent that other MAbs 
could not bind, or the competition was low because of some steric hindrance. 
Antigenic site A apparently appears to be similar to the antigenic site A'. Antigenic 
site E appears to a large extent to be similar to site B. Antigenic site C is similar to 
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Competitive Inhibition: Q <30%  ^30-50% B =*50% 
Figure 6. Competitive binding of anti-N MAbs. Unlabeled MAbs were incubated 
for ISh at room temperature in microtiter plates, coated with BRSV 
antigen and then biotinylated MAbs were added. After 2h incubation at 
37°C, bound antibody was detected using peroxidase labeled streptavidin 
and ABTS enzyme substrate. The results are expressed as percent 
competitive inhibition. 
Competing MAbs 
65-16 
Antigenic 
area 
(epitope) 
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Table 3. Competitive ELISA between non-biotinylated and biotinylated MAbs 
Biotinylated Percent competition with the following competing MAbs 
25-0 25-3 38-7 38-9 61-1 61-7 65-12 65-16 
25-0 68.7 62.2 62.2 76.7 61.5 50.0 52.3 62.0 
25-3 70.3 63.9 66.2 81.6 61.9 54.3 59.5 79.2 
38-7 7L1 58.9 65.8 83.3 68.3 63.9 68.8 79.1 
38-9 70.7 67.2 71.2 74.7 66.1 65.4 69.2 77.2 
61-1 34.0 23.1 64.6 68.1 62.0 60.1 62.1 51.1 
61-7 41.9 23.4 70.6 73.2 68.0 67.7 76.7 54.2 
65-12 19.0 52.9 58.0 68.4 39.7 36.6 42.9 65.0 
65-16 27.5 46.0 46.8 68.2 50.0 51.2 54.9 66.5 
Competitive binding of anti-N MAbs. Unlabeled MAbs were incubated for 18h at 
room temperature in microtiter plates, coated with BRSV antigen and then 
biotinylated MAbs were added. After 2h incubation at 37'C, bound antibody was 
detected using peroxidase labeled streptavidin and ABTS enzyme substrate. The 
results are expressed as percent competitive inhibition. 
Table 4. Competitive ELISA between non-biotinylated and biotinylated MAbs 
Biotinylated Percent competition with the following competing MAbs 
MAb 25-0 25-3 38-7 38-9 61-1 61-7 65-12 65-16 
25-0 61.8 60.7 70.7 73.6 65.4 67.4 68.2 74.2 
25-3 21.2 44.0 65.5 52.8 47.8 46.6 50.3 62.6 
38-7 43.8 50.0 62.0 67.6 66.0 66.2 67.7 73.9 
38-9 18.4 19.8 38.9 40.2 38.7 41.4 47.7 46.0 
61-1 38.6 41.9 58.5 66.4 52.3 57.5 55.5 55.5 
61-7 43.9 48.4 63.5 69.7 68.7 70.6 68.2 68.0 
65-12 53.6 61.4 72.5 80.2 65.1 65.2 72.7 80.3 
65-16 44.1 47.1 61.2 74.2 45.3 51.0 50.0 71.4 
Competitive binding of anti-N MAbs. Biotinylated MAbs and unlabeled MAbs were 
put together in microtiter plates, coated with BRSV. After 2h at 37°C, bound 
antibody was detected using peroxidase-labeled streptavidin and ABTS enzyme 
substrate. The results are expressed as percent competitive inhibition. 
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Biotinylated 
MAb 
Competing MAbs Antigenic 
area 
(epitope) 25-0 25-3 1 38-7 1 38-9 1 61-1 61-7 1 65-12 1 65-16 
25-0 A' 
25-3 B' 
38-7 C 
38-9 D' 
61-1 
61-7 
E 
65-12 A' 
65-16 F 
Competitive Inhibition; <30% 30-50% H >50% 
Figure 7. Competitive ELISA of anti-N MAbs. Biotinylated MAbs and unlabeled 
MAbs were put together in microtiter plates, coated with BRSV. After 2h 
at 37°C, bound antibody was detected using peroxidase-labeled streptavidin 
and ABTS enzyme substrate. The results are expressed as percent 
competitive inhibition. 
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A and A' but it shows a lower competition with MAb 25-0. The remaining two 
antigenic sites, namely B' and F, appear to be markedly distinct from other sites. 
Discussion 
A panel of MAbs specific for N protein of BRSV were generated by priming 
BALB/c mice with three different viral preparations. Each preparation induced a 
different immune response, which is in agreement with the recognized principle that 
the type of adjuvant and manner of preparation of antigen can effect the immune 
response. '^ These MAbs can be divided into four different groups according to their 
Ig class and subclass. 
The immunofluorescence pattern we observed with these MAbs revealed localized 
nucleoprotein in the intracellular location early in the infection cycle. Neither 
annular fluorescence nor peripheral filamentous extensions protruding from the cell 
surface was observed as has been reported '^ with MAb raised against N protein of 
HRSV. 
Immunoprecipitation of radiolabeled proteins is a conunonly used procedure for 
identifying the protein specificity of MAbs^^. Radioimmunoprecipitation assays 
conducted during this study further confirmed that the generated MAbs were against 
the N protein because the molecular weight of the precipitated protein was found to 
be 43 Kd. In addition, the MAbs did not precipitate with cell protein. The 
molecular weight of N protein of HRSV and BRSV has been reported to be 41 Kd to 
44 Kd and 43 Kd respectively."-"'®* '' 
To characterize the interrelationship of the MAbs against the N protein of BRSV 
and its epitopes, we used two procedures of a competitive binding assay^®'^ ^ based on 
the biotin avidin system and ELISA. This assay measured the extent of competition 
between competing and non competing MAbs. Failure of unlabeled antibody to 
reduce the binding of labeled antibody, provided evidence that the antibodies bind to 
distinct sites on the antigen. However, this could also be due to the fact that the 
labeled antibody binds with higher avidity than the unlabeled competitor to an 
overlapping epitope.^ 
Both one way and two way competition was observed between some of the MAbs 
in both the procedures. Two way blocking between two MAbs suggests, but does not 
prove, that they react with the same or an overlapping epitope. Conformational 
changes as well as steric hindrance can result in blocking between two MAbs which 
otherwise would not have had a blocking effect. Similarly, the lack of blocking 
between two MAbs suggests, but does not prove, that these MAbs react with distinct 
antigenic sites or epitopes. '^ The lack of blocking could be one-way or two-way. 
The former could be due to differences in avidity and the latter could be an artifact of 
the preparations of the viral antigen used as the immunogen. '^ Three procedures 
were used in this study for the preparation of viral antigen for immunizing. There is 
a good possibility that two or more populations of the same protein could be 
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produced having conformational or altered epitope resulting in differences in their 
reactivity with different MAbs/* 
Keeping in view some of the above referred limitations we used two procedures 
whereby the labeled and unlabeled MAbs were applied together or one after the other 
sequentially. The application of labeled and unlabeled MAbs was also reversed. Our 
competitive assays presumptively identified 4 to 6 antigenic sites on the N protein of 
BRSV. Some of them were similar and others appeared quite distinct. One example 
would be antigenic site D' (Fig. 5). It appears that binding of unlabeled MAbs 
altered the site to such an extent that the labeled MAb is far less competitive. In the 
other procedure, this MAb has over 50% competition with all the other MAbs, 
indicating that most probably the procedure itself has had a marked effect on the 
competition between MAbs. Based on the competitive binding ELISA test, 15 
epitopes have been reported on the N protein^^ of HRSV. 
All the data indicate that the MAbs generated in this study are specific for the N 
protein of BRSV and that there are at least 4-6 antibody-binding sites on the N 
protein. 
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IMMUNIZATION AGAINST BOVINE RESPIRATORY SYNCYTIAL VIRUS 
wrra SOLID MATRK-ANTIBODY-ANTIGEN COMPLEXES 
CONTAINING N PROTEIN OF THE VIRUS 
A manuscript to be submitted to American Journal of Veterinary Research 
Muhammad Zuliiqar, Merlin L. Kaeberle, Kenneth B. Piatt, Michael C. Meetz 
Microbiology, Immunology and Preventive Medicine, Iowa State University, 
Ames, lA 50011 USA 
Summary 
In the present study two monoclonal antibodies, specific for N protein of BRSV, 
65-12 (IgM) and 38-6 (IgGjJ were used to make antibody-antigen complexes by 
incubating these with BRSV infected cell lysate. The antibody-antigen complexes 
were adsorbed to a solid matrix by incubating these complexes with antimouse IgM-
agarose and Protein A-agrose beads according to the isotype of the MAbs. The 
SMAA complexes so formed were washed five times with PBS, suspended in an 
equal quantity of aluminum hydroxide gel and used for immunization of two groups 
of lambs. Immune responses were monitored by the lymphocyte transforming assay 
(LTA), western immunoblot assay (WIA) and serum neutralization (SN) assay. 
In vaccinated groups, the maximum immune response in terms of SI* (stimulation 
index), determined by LTA, was observed on day 11 postvaccination. However, the 
response of animals in group B, vaccinated with SMAA complexes containing MAb 
(IgM), was significandy higher than that of the group C, vaccinated with SMAA 
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complexes containing MAb (IgG2j. Immune responses were also determined by the 
western immunoblot assay. By 11-days postvaccination four animals from group B 
exhibited a marked response (band) to the N protein and three animals from group C 
showed a very faint band at the same position. WIA did not detect F or G proteins. 
Challenging 21 days postvaccination with heat inactivated BRSV resulted in a 
dramatic neutralizing antibody responses in lambs primed with SMAA complexes. 
Appreciable titers were present in the sera five days following inmiunization and 
titers peaked at 14 days. In contrast, antibody titers were barely detectable in control 
animals at five days and relatively low titers were present even at 21 days. This 
clearly indicated enhanced responses to neutralizing epitopes associated with F and G 
proteins and this was confirmed by WIA conducted on these sera. We conclude that 
immunization with N protein primed these animals for a response to other structural 
proteins of the virus. 
Introduction 
In spite of all efforts and modem scientific developments, bovine respiratory 
' disease (BRD) continues to be an enigma for the cattle industry of many countries 
including the United States of America. It has been estimated that 40-80% of all 
diseases of catde involve the respiratory system.' In the United States alone it causes 
a loss of 250-750 million dollars annually.^ Baker' cited a 1977 Livestock 
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Conservation Institute estimate of one billion dollars loss due to BRD per year in 
North America. 
Bovine respiratory syncytial virus (BRSV) is one of the most frequently occurring 
and virulent etiological agents of respiratory tract disease in calves. '^^  Virus isolation 
and seroepizootiological surveys have indicated that exposure of cattle to BRSV is 
widespread in many countries.^*®'®'''*'' 
Human as well as bovine respiratory syncytial virus belong to the genus 
Pneumovirus of the family Paramyxoviridae.'" Both viruses are antigenically 
related" and cause the greatest morbidity in their respective species during the first 
six months of life when maternal immunity is still present. Reinfections are conunon 
and difficulties have been encountered in providing protection through live or 
inactivated vaccines against respiratory syncytial viruses.'^  A major limitation of 
these vaccines is that maternally derived immunity to BRSV suppresses an active 
immune response to vaccination in calves."'" The basis for this suppression is not 
well understood. It may result from the blocking effect of the specific antiviral 
antibodies. Nelson et al.'^  reported that seronegative calves responded to the primary 
vaccination with immunopurified F protein by producing antibodies. Subsequent 
vaccination did not boost the response, suggesting that already existing anti F 
antibody suppressed the immune response. 
The genome of the respiratory syncytial viruses codes for ten proteins, including 
two nonstructural (IB and IC) and eight structural proteins.The major 
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glycoprotein (G), fusion protein (F), lA protein and 22Kd proteins are components of 
the viral envelope. The nucleocapsid contains the nucleocapsid protein (N)> the 
phosphoprotein (P), and the large protein (L). The matrix protein (M) forms a 
structural layer between the envelope and the nucleocapsid." Antibodies to all the 
structural proteins develop in convalescent calves (6 to 7 month old), but the 
predominant response is directed against the F and N proteins.'^  Similarly, in a 
limited study, 2 to 3 week old calves have been reported to have moderate levels of 
maternal antibodies to the F and N proteins against BRSV.'^  
A number of workers have analyzed the antibody response to N protein of HRSV 
in experimental animals with variable results. King et al.'* reported that N protein 
expressed in vaccinia virus afforded a significant degree of protection to challenge in 
BALB/c mice. Although vaccination with the recombinant expressing N protein 
resulted in a significant reduction in titer in the lung of the mice following live virus 
challenge, the protection was not as solid as provided by G and F proteins expressed 
and used similarly."'^ " Peretz et al. '^ have reported that G and F but not N protein 
induced protection in BALB/c mice. Immunity induced by G or F proteins lasts 
longer than that induced by N protein.^ These observations suggest that N protein is 
not as immunogenic as the G and F proteins and thus maternal antibody to the N 
protein may drop below detectable levels sooner than antibody to the F protein. Our 
own preliminary studies (unpublished data) in which the specificity and duration of 
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maternal antibody was studied suggested that antibody to the N protein drops below 
detectable levels before antibody to the F protein. 
The N protein probably plays a role in RSV-specific cytolytic T-cell responses," 
because N protein served as a target for RSV-specific Tc cells in both mouse and 
human studies.'®*" It is therefore reasonable to assume that the N protein of BRSV 
may also serve as a target for bovine Tc cells. 
The role of nucleocapsid protein as a protective antigen has also been described 
for the morphologically similar influenza virus. Over a series of experiments 75 % 
mice were protected and the protective response induced by the nucleocapsid protein, 
like that induced by N protein of RSV, appeared to be cell mediated in nature.^"* 
Immunization of mice with solid matrix-antibody-antigen complexes (SMAA), 
containing either internal or external structural proteins from the same virus (Simian 
virus 5) or from different viruses (herpes simplex virus, influenza virus, measles 
virus and simian virus), have been reported to induce vigorous humoral and cell 
mediated immune responses."'^ ®*"*^® The N protein of BRSV has not been used as 
immunogen in any form individually. Through this study it was envisaged to use 
SMAA complexes containing N protein of BRSV to investigate its immunogenicity in 
lambs and to determine the carrier effect on subsequent challenge with heat 
inactivated virus. Several workers have reported successful vaccination with proteins 
from virus incorporated into SMAA complexes. 
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Materials and Methods 
Cells and viruses - Vero cells (Veterinary Diagnostic Laboratory, College of 
Veterinary Medicine, ISU., CRL 1587 Vero 76 from American Tissue Culture 
Collection) were maintained on Dulbecco's Modified Eagles's Medium [(DMEM), 
Sigma Chemical Company, St. Louis] supplemented with 10% betapropiolactone-
treated fetal calf serum (Sigma) and 50 ng/wl of gentamicin (Schering Corporation, 
Kenilworth, NJ). 
Propagation of virus - Vero cells grown in 175 cm^ tissue culture flasks (Costar 
Corporation, Cambridge, MA) were inoculated with BRSV strain 375 when the 
monolayer was subconfluent and incubated in a humidified chamber with 5 % CO2 at 
37''C. A low titer of virus i.e., 10?/ml was obtained up to day 3 to 4 postinfection. 
Modification of the culture procedure resulted in a methodology that routinely yielded 
a titer of 10®'^ /ml. 
Cells were infected with virus (2xlOVml) when the monolayer was about 80% 
complete. When viral cytopathic effect (CPE) was initially observed, usually 44-50h 
postinfection, the cells were trypsinized and transferred with equal quantity of 
trypsinized uninfected Vero cells to a 225 cm^ flask (Coming Incorporated, Coming, 
NY). On further incubation (24-48h post infection), 90-100 % CPE was present and 
the cells were harvested to prepare vaccine, for immunization of lambs and antigen 
for lymphocyte blastogenesis and western immunoblot assay (WL\). 
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Preparation of SMAA complexes 
Preparation of cell lysate: BRSV infected Vero cells showing 90-100% CPE 
were centrifiiged at 2000 g for ten min. The pellet was washed twice in DMEM 
(serum free). After the second washing, lysate buffer (150mM-NaCl, 1 % sodium 
deoxycholate, 1% Triton-x-lOO, 0.1% SDS, lOmM-Tris-HCl pH 7.4) was added at a 
10 X volume of the pellet and stirred overnight at 4°C. The preparation was again 
centriftiged as before and the supernatant fluid was collected. The cell lysate was 
sonicated for 30 seconds at 6.5K, 50% cycle on ice, centrifiiged and supernatant 
collected. 
Preparation of antigen-antibody complexes: Tissue culture supematants from 
two monoclonal antibodies (MAb) 65-12 (IgM) and 38-6 (IgGja), specific for N 
protein of BRSV, were used for preparation of antigen-antibody complexes. Five ml 
each of the MAb supernatant was incubated overnight at 4°C with 12.5 ml of cell 
lysate on a rocker platform. 
Preparation of washed SMAA complexes: The antigen-antibody complexes 
consisting of cell lysate and MAb 65-12 or 38-6 were adsorbed onto a solid matrix by 
addition of six ml of anti-mouse IgM-agarose (Sigma) and 1.25 ml protein A-agrose 
beads (Sigma) respectively and incubated for another 4h at 4°C. The SMAA 
complexes so formed were washed five times with phosphate buffered saline (PBS, 
pH 7.2) by centrifugation at 2000 rpm for ten min and adjusted to 10 ml by addition 
of PBS. The SMAA complexes were suspended in an equal quantity (v/v) of one 
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percent aluminum hydroxide gel (Intergen Company, Purchase, NY) for 
immunization of lambs. 
Experimental design 
Immunization: Fifteen lambs, five to six months of age and seronegative to 
BRSV, were randomly divided into three equal groups. One group served as a 
control and the other two groups were immunized with SMAA complexes. 
Group A served as a control. All animals were injected with one ml of 0.5 % 
aluminum hydroxide gel subcutaneously at a site on each side of the neck. 
Group B animals were injected subcutaneously with two ml of SMAA complexes 
consisting of N protein of BRSV, MAb (IgM), antimouse IgM-agrose and aluminum 
hydroxide gel at a site on each side of the neck. 
Group C was injected subcutaneously with two ml of SMAA complexes consisting of 
N protein of BRSV, MAb OfgG2a), Protein A-agrose beads and aluminum hydroxide 
gel at a site on each side of the neck. 
Blood samples (30 ml) were collected prior to immunization and on days 7, 11, 
15 and 21 postvaccination for lymphocyte blastogenesis, western immunoblot assay 
(WIA) and serum neutralization (SN) assays. For serum, blood was allowed to clot 
overnight and then centrifuged for 30 min at 2000 rpm after which the serum was 
collected, aliquoted and stored at -20°C. 
Challenge: BRSV-infected Vero cell suspension (300 ml, titer lO'-^/ml) was 
inactivated at S6°C for 30 min.^^ This virus preparation was lyophilized and 
reconstituted in 30 ml PBS and dialyzed against two changes of PBS for 36h at 4°C. 
all animals were injected s/c with 2 ml of the virus preparation three weeks after 
primary vaccination. 
All animals were bled and serum harvested on days 5, 8, 11, 14 and 21 after 
challenge with inactivated virus. The immune response was monitored by WIA and 
SN assay. 
Lymphocyte blast transforming assay - The lymphocyte transforming assay was 
conducted by measuring the incorporation of ^H-thymidine into DNA by cultured 
lymphocytes. For this purpose the peripheral lymphocytes were harvested from the 
anticoagulated venous blood according to a modified procedure of Boyum.^° 
Histopaque 1077 (Sigma) was diluted with 13% Hank's balanced salt solution (HBSS, 
without calcium and magnesium, Gibco Laboratories, Grand Island, NY). Briefly 
seven ml of diluted blood were carefully layered onto four ml of prewarmed 
Histopaque and centrifiiged at 250 g for 30 min. The lymphocyte-rich interface was 
aspirated with a pipet and transferred to a tube containing a 2X volume of HBSS and 
again centrifiiged at 150 g for 15 min. The supernatant was decanted and the pellet 
resuspended in four ml of HBSS. Cell concentration was determined with a Coulter 
Counter (Coulter Electronics Inc., Hialeah, FL). Trypan blue was used for 
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detBrmining the viability of the cells and only those preparations were processed for 
blastogenic assay which had more than 80% viable cells. Each cell sample was 
diluted to a concentration of 200,000 cells/200 fil with diluting media containing 89% 
RPMl (Gibco), one percent antibiotic-antimycotic 100 X (Penicillin-G, Streptomycin 
sulphate and Amphotericin-B, Sigma) and 15% fetal calf serum (Intergen). An 
aUquot of 200 fil of diluted cell suspension was dispensed in flat bottom 96 well cell 
culture plates. Three wells were used for each mitogen and antigen per animal and 
three wells were left as untreated controls for each animal. The mitogens were used 
at a dose rate of 25 fil mitogen (6.25 /ig)/well and the same quantity of the medium 
was added to cells of the control wells. BRSV antigen prepared according to a 
protocol of Bruckova et al.,^^ was used at a protein concentration of 60 /ig/well. The 
plates were incubated for 72h at 3TC in a CO2 incubator. The plates were labeled 
with ^H-thymidine (0.75 /iCi/well; ICN, Irvine, CA) and incubated for another 18h. 
The cells were harvested on fiberglass filters with a PHD cell harvester (Cambridge, 
Watertown, MA). Filter paper discs were transferred to scintillation vials containing 
Scintiverse BD (Fisher Scientific, Pittsburgh, PA) and the radioactivity determined 
with a scintillation counter (Packard Instrument Co., Downers Grove, IL). The 
stimulation index (SI) was calculated by dividing the mean value of stimulated 
lymphocyte cell cultures by the mean value of the unstimulated lymphocyte cell 
cultures from a single animal. The results were analyzed by analysis of variance 
with a 95% confidence level. 
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Western Immunoblot Assc  ^
Preparation of antigens: BRSV-infected cells showing 90-100% CPE were 
centrifiiged at 2000 g for ten min. The pellet was washed twice in DMEM (serum 
free). After a second washing, lysate buffer (150mM-NaCl, 1 % sodium 
deoxycholate, 1% Triton x-100, 0.1% SDS, lOmM-Tris-HCl pH 7.4) was added at a 
10 X volume of the pellet and stirred overnight at 4°C. The preparation was 
centrifiiged, the supernatant was collected and the protein content determined by the 
BCA protein assay (Bio-Rad Laboratories, Hercules, CA) and adjusted to 4 mg/ml 
with PBS. This preparation was boiled at 100°C for five minutes with an equal 
volume of sample buffer consisting of 2% SDS, 50% glycerol and 0.05% 
bromophenol blue in 0.5M Tris buffer (pH 6.8). This viral antigen (100 ul) was run 
through 10% SDS-PAGE^^ to resolve viral proteins. 
SDS-PAGE analysis: A vertical slab mini-gel apparatus (Bio-Rad) was used for 
electrophoresis as directed by the manufacturer. Prestained SDS-PAGE standards 
(Bio-Rad) ranging from 18.5-106 Kd were used as molecular mass standards. For 
immunoblotting the electrophoresed proteins along with molecular weight markers 
were electrophoretically transferred to a 0.45 ii nitrocellulose membrane (Bio-Rad). 
Transfer was carried out at 4°C for 90 min at 100 volts in transfer buffer consisting 
of 25mM Tris, 192mM glycine, and 20% v/v methanol (pH 8.3). 
Immunoblot assay procedure: The nitrocellulose membrane having separated 
proteins was blocked overnight at 4°C in TBS (500 mM NaCl, 20mM Tris, pH 7,5) 
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containing 1% gelatin (Difco Laboratories, Detroit, Michigan), The membrane was 
washed for three five minute cycles in TTBS (TBS containing 0.05 % Tween 20) on a 
rocker platform. The membrane was incubated with test lambs serum or MAb 
specific for N protein '^ diluted 1:100 in PBS (pH 7.2) for one hour at room 
temperature on a rocker platform. Miniblotters 16 and 28 (Tmmunetics, Cambridge, 
MA) were used for incubating the serum and MAb. The membrane was again 
washed and incubated in peroxidase-labeled anti species IgG (L+H) antibody (KPL) 
for one hour at room temperature on a rocker platform. The membrane was washed 
and bound IgG was visualized by immersing the membrane in three component TMB 
membrane peroxidase substrate (KPL). The color reaction was allowed to develop 
for 2-3 minutes and then stopped by three brief washes in deionized water. The 
molecular weights were determined by comparison with the protein standards '^* and 
image analysis. 
Serum virus neutralization assay - Serum-virus neutralization (SN) was performed on 
lambs serum samples as described previouslyBriefly, all sera were heat 
inactivated at 56°C for 30 min. Two-fold dilutions of sera were made in MEM in 
microtiter plates (Costar) in a way that each well contained 50 ul of serum dilution. 
Virus was diluted to 100 TCIDjo/50 /xl, in MEM and added to all wells at the rate of 
50 ul/well, and the mixture incubated at 37°C for one hour. A suspension of 
approximately 2x10* BT cells/well was added in 150 ul of growth media and the 
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plates incubated in a COj incubator at 37°C for one weak. The serum-virus 
neutralization titer was the highest dilution of serum in which 50% of the cells in a 
well were protected from the viral CPE. The results were analyzed by analysis of 
variance with a 95 % confidence level. 
Results . 
Lymphocyte transformation responses - All the results are the mean of triplicate 
cultures. The peripheral blood lymphocyte blastogenic response in the form of 
stimulation index (SI), as measured by the uptake of ^H-thymidine by DNA of 
lymphocytes of the lambs in all groups, are presented in Table 1. The mean SI of 
BRSV antigen-stimulated cultures significantly increased in both immunized groups 
(Table 1) as compared to the control group. However, the response in group B, 
vaccinated with SMAA complexes containing MAb (IgM), was significantly higher 
than group C, vaccinated with SMAA complexes containing MAb (IgGaJ (Fig. 1). 
The SI in group B continuously increased from 1,26 + 0.66 before vaccination to 
2.99 ± 1.89 at 7 days and 3.20 + 1.60 at 11 days postvaccination. Even at 21 days 
postvaccination the SI of group B was apparently higher than the group C and the 
control group, but statistically it was insignificant. The maximum response in both 
the vaccinated groups occurred at day-11 postvaccination. However, in group C the 
response was of low magnitude, declined by 15 days postvaccination and was 
essentially equivalent to the control group on day-21 postvaccination. 
Table 1. Antigen induced stimulation indexes (mean±SE) of different groups of lambs 
Days - postvaccination 
Group* Dav-0 Dav-7 Dav-11 Dav-15 Dav-21 
Ag Ag Ag Ag Ag 
A 1.11" ± 0.15 1.23'" ± 0.29 1.21'' ± 0.17 1.13'' ± 0.20 1.22' ± 0.19 
B 1.26' ± 0.29 2.99" ± 0.84 3.20' ± 0.71 2.84" ± 0.55 2.12' ± 0.65 
C 1.33* ± 0.16 1.09'' ± 0.07 2.44'* ± 0.58 1.06'' ± 0.18 1.22' ± 0.14 
LSD 0.65 1.60 1.67 1.09 1.22 
*Each group had five lambs. 
LSD = least significant difference (P=0.05). 
Means with same superscript not significantly different based on the LSD. 
Peripheral blood lymphocytes were cultured with BRSV antigen at a protein concnetration rate of 60 ^g/well, before 
vaccination as well as after vaccination, as indicated above. After 96 hours the cultures were labeled with 
thymidine and harvested at 18 hours later. Stimulation indexes (SF) are average of three wells. The SI' were 
calculated by dividing the stimulated mean value of lymphocyte cell cultures by the mean value of the unstimulated 
lymphocyte cell cultures of the respective wells. 
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Figure 1. Peripheral blood lymphocytes were cultured with BRSV antigen at a 
protein concentration rate of 60 jug/well, before vaccination as well as 
after vaccination. After 96 hours the cultures were labeled with 
thymidine and harvested at 18 hours later. Stimulation indexes (SI*) are 
average of three wells. The SI' were calculated by dividing the stimulated 
mean value of lymphocyte cell cultures by the mean value of the 
unstimulated lymphocyte cell cultures of the respective wells. Error bar 
is standard error of mean. 
Western Immunoblot Assay - The immune response was determined by western 
inununoblot assay (WIA) using the serum which was collected on day 0, 7, 11, 15, 
and 21 postvaccination. The MAb specific for N protein^^ was also used in the WIA 
for comparison purposes. Seven days postimmunization two animals from group B 
showed a marked response (band) to the N protein; by 11-days postvaccination four 
animals from group B exhibited a marked (response) band to the N protein and three 
animals from group C showed a very faint band at the same position (Fig. 2). One 
of the animals from group B also showed a band at the 36 Kd position 11-days 
postvaccination but a reaction was not apparent at 15 days postvaccination. The 
remaining animals including controls did not show any visible reactivity to the N 
protein or other constituents of the virus. 
The nature of the immune response was also determined by WIA after challenge. 
Serum from all animals of group B reacted with the N protein and a marked band 
was visible 8-days postimmunization. A marked band was also visible at the 36 Kd 
position, which probably represents the P protein of BRSV strain 375. Three animals 
from group C also showed a marked response to the N protein and one showed a 
comparatively faint band at the N protein position; the remaining one animal did not 
show any band at N protein level, but it showed a marked band at 36 Kd. Serum 
from control animals was not reactive at 8 days postchallenge (Fig. 3). However, by 
day 11 most of the control animals exhibited a visible band at the N protein position 
and one showed a weak response at 36 Kd level (Fig. 4). By day 14, serum from 
Figure 2. Analysis of the lambs serum, 11-days postvaccination with washed SMAA 
complexes by western immuonoblot assay. Lane 1-5 represent serum of 
the group B, immunized with SMAA complexes containing N protein 
specific MAb (IgM). Lane 6 represent N protein MAb raised against 
HRSV diluted 1:100 in PBS. Lane 7-11 represent serum of the group C, 
immunized with SMAA complexes containing N protein specific MAb 
(IgG2j. Lane 12-15 represent serum of control group A. Lane 15 
represents serum of two control animals. The N protein is indicated on 
the basis of reactivity with The MAb specific for this protein. 
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Figure 3. Analysis of the lambs serum, 8-days postchallenge with washed SMAA 
complexes by western immuonoblot assay. Lane 1-S represent serum of 
the group B, inmiunized with SMAA complexes containing N protein 
specific MAb (IgM). Lane 6-10 represent serum of the group C, 
immunized with SMAA complexes containing N protein specific MAb 
(IgG2j. Lane 11 represent N protein MAb raised against HRSV diluted 
1:100 in PBS. Lane 12-16 represent serum of control group A. The N 
protein is indicated on the basis of reactivity with The MAb specific for 
this protein. However P protein is indicated on the basis of molecular 
weight, which is reported to be 36 Kd (Baker et al., 1992). 
Figure 4. Analysis of the lambs serum, 11-days postchallenge with washed SMAA 
complexes by western immuonoblot assay. Lane 1-5 represent serum of 
the group B, immunized with SMAA complexes containing N protein 
specific MAb (IgM). Lane 6 represent N protein MAb raised against 
HRSV diluted 1:100. Lane 7-11 represent serum of the group C, 
immunized with SMAA complexes containing N protein specific MAb 
(IgGzJ. Lane 12-16 represent serum of control group A. The N protein 
is indicated on the basis of reactivity with The MAb specific for this 
protein. However P protein is indicated on the basis of molecular weight, 
which is reported to be 36 Kd. 
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control animals elicited reactivity with N protein but the response was much weaker 
than serum from the vaccinated groups. Sera from primed animals was reactive with 
several viral proteins by 14 days post booster immunization and that reactivity 
became more pronounced by day-21 postchallenge as indicated in Figure 5. 
Serum neutralization assay - Neutralizing antibodies could not be detected in sera of 
all animals prior to vaccination and challenge. By the fifth day following challenge 
aU animals in the primed groups (B and C) had developed neutralizing antibody 
titers. A dramatic increase in neutralizing antibody titers occurred by day 8 and 
these persisted through the 21-day experimental period. Most animals in the control 
group responded (4 of 5) but the response was very low (Tables 2 and 3). 
Virus neutralizing antibody titers were higher in serum of animals in group B as 
compared to group C (Fig. 6). However, the difference was not statistically 
significant. 
Table 2. Distribution of SN titres (log2) of lambs 3 weeks postchallenge 
Group No 
of 
Lambs 
SN titer Oogi) distribution of lambs 
<1 2 3 4 5 6 7 8 
A 5 1 2 2 - -
B 5 - 2 1 2 
C 5 - 2 2 1 -
Figure 5. Analysis of lambs serum, 21-days postchallenge with washed SMAA 
complexes by western immuonoblot assay. Lane 1-S represent serum of 
the group B, immunized with SMAA complexes containing N protein 
specific MAb (IgM). Lane 6-10 represent serum of the control group. 
Lane 11-15 represent serum of group C, immunized with SMAA 
complexes containing N protein specific MAb (IgG^J. Lane 16 represent 
hyperimmune serum raised against BRSV in sheep. The N protein is 
indicated on the basis of reactivity with the MAb specific for this protein. 
However other proteins including F^, F„ Fj, P, M and 23 Kd are 
indicated on the basis of their apparent molecular weights as reported in 
the literature (Mallipeddi et al., 1990; Baker et al., 1992). There are 
several other protein bands which are most probably cell band or some 
viral proteins which are not reported. 
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Table 3. Group wise SN titer (log 2) (mean±SE) of different groups 
Days - postchallenge 
Group* Day-0 Day-5 Day-8 Day-11 Day-14 Day-21 
A — 0.4tf ± 0.25 0.60'' ± 0.40 1.4tf' ± 0.51 Leo"- ± 0.51 2.20*" ± 0.37 
B ... 3.20* ± 0.49 5.80" ± 0.37 6.20» ± 0.49 6.40^ ± 0.68 6.40* ± 0.68 
C — 2.80* ± 0.37 5.00" ± 0.32 5.20" ± 0.37 5.80* ± 0.37 5.80« ± 0.37 
LSD — 1.18 1.13 1.42 1.65 1.53 
*Each group had five lambs. 
LSD = least significant ditference (P=0.05). 
Means with same superscript not significantly different based on die LSD. 
Serum neutralizing antibody responses of vaccinated and control groups following challenge with heat inactivated 
BRSV. The serum-virus neutralization titer was the highest dilution of serum in which 50% of the cells in a well 
were protected from the viral CPE. The results were analyzed by analysis of variance with a 95% confidence level. 
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Figure 6. Serum neutralizing antibody responses of vaccinated and control groups 
following challenge with heat inactivated BRSV. The serum-virus 
neutralization titer was the highest dilution of serum in which 50% of the 
cells in a well were protected from the viral CPE. The results were 
analyzed by analysis of variance with a 95 % confidence level. 
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Discussion 
In the present study two monoclonal antibodies specific for N protein of BRSV, 
65-12 (IgM) and 38-6 (IgG2j, were used to make antibody-antigen complexes by 
incubating these with BRSV-infected cell lysate. SMAA complexes were prepared by 
incubating the antibody-antigen complexes with antimouse IgM-agarose or Protein A-
agarose beads according to the isotype of the MAbs. The SMAA complexes so 
formed were washed five times with PBS, suspended in an equal quantity of 
aluminum hydroxide gel, and used for immunization of two groups of lambs. The 
immune response was monitored by the lymphocyte transforming assay (LTA) and 
western immunoblot assay (WIA) and serum neutralization (SN) assay. 
Enhanced lymphocyte blastogenic resopnses occurred on stimulation of cultured 
lymphocytes from vaccinated animals with viral antigen. Peak responses were noted 
on day 11 postvaccination in both groups, but of the responses of group B, vaccinated 
with SMAA complexes containing MAb (IgM), was significantly higher than the 
group C, vaccinated with SMAA complexes containing MAb (lgG2a). The mean 
stimulation index of BRSV antigen stimulated cultures significantly increased from 
1.47 ± 0.32 before challenge to 3.46 + 1.64 five days after challenge. 
Lymphocytes from the lambs were responsive in LTA until 21 days and 11 days 
postvaccination in group B and C respectively, which indicated that the SMAA 
complexes containing MAb (IgM) induced higher and prolonged responses than the 
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SMAA complexes containing MAb (IgGjJ. Because of the difficulty in reproducing 
experimental BRSV infections in calves, studies on the effect of challenge on cellular 
immune responses are lacking.^^ Recently Ellis et al. '^' reported a significant increase 
in proliferative responses of catde lymphocytes to live BRSV by day 7 after primary 
immunization with a vaccine containing inactivated BRSV. Sharma and 
Woldehiwe^®*^® have reported contrasting results regarding BRSV antigen stimulation 
in vitro after primary infection and reinfection. They did not monitor any significant 
lymphocyte transformation responses in experimentally-infected lambs up to 21 days 
after inoculation. However, these lambs when challenged seven months after primary 
infection showed significandy higher responses to BRSV antigen in vitro than the 
control lambs. 
In this study we also analyzed the humoral response of all animals by WIA. Sera 
from most of the vaccinates ie., 80% from group B reacted strongly with the N 
protein as indicated by a band at the N Protein location and 60% from group C 
exhibited a very faint band at the same position, 11-days postvaccination. Thereafter, 
the reactivity determinable by WIA appeared to decline. Similar findings have been 
reported with N protein expressed in vaccinia by Connors et al.^ These findings are 
also to some extent supported by an earlier report which indicated that 
radioimmunoprecipitating antibodies were induced in BALB/c mice after 21 days of 
vaccination with N protein expressed in vaccinia virus. None of the lambs 
developed a SN antibody titer after vaccination. 
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The findings of this experimentation indicate that SMAA complexes formed >vith 
the N protein of BRSV are highly immunogenic in lambs. Further, they are capable 
of inducing both humoral and cell-mediated immunity. Inununization of mice with 
solid matrix-antibody-antigen complexes, containing either internal or external 
structural proteins from the same virus (Simian virus 5) or from different viruses 
(herpes simplex virus, influenza virus, measles virus and simian virus), have been 
reported to induce vigorous humoral and cell mediated immune responses."'^ ® "'^  
A challenge dose of heat-inactivated BRSV 21 days following the priming 
injection resulted into a £ar better SN titer in the SMAA complex vaccinated groups 
than in the control group. Not only did vaccinated animals develop a higher titer but 
the response developed earlier since all animals seroconverted within five days of 
challenge. The immune response further increased and peaked by 14 days 
postchallenge. In comparison, the control group responded very slowly and 
maximum response was not observed until 21 days postchallenge. The titer was quite 
low as compared to the vaccinated groups. Among the vaccinated groups, the highest 
SN titer was observed in the group vaccinated with the SMAA complexes containing 
MAb agM). 
These results indicate that vaccination with N protein incorported in SMAA 
complexes sensitized the lambs and this contributed to a carrier effect resulting into 
increased SN titer in the vaccinated groups following a challenge with inactivated 
virus. It appears that primary vaccination induced T and B lymphocytes reactive with 
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N protein. Consequently when lambs were boosted, because of the presence of 
induced lymphocytes, there was an increased response to the N protein as compared 
to unvaccinated lambs. Sensitized helper T lymphocytes also probably provided help 
to B lymphocytes reactive with other viral proteins. This resulted in an enhanced 
humoral response to other viral proteins including those involved in virus 
neutralization. 
Antibody-antigen complexes are known to enhance the inmiune response and have 
been used for inducing both humoral and cell-mediated immune responses. '^ The 
antibodies bind to their antigens forming immune complexes and thus promote the 
ingestion of antigen by monocytes through antibody-monocyte FcR interaction and 
enhance antigen processing and presentation. Such antibody potentiating effect 
occurs in vivo and probably plays a significant role in the induction of immune 
response.^ 
Monoclonal antibodies can be attached to particulate solid matrices and the solid 
matrix-antibody complexes can then be used to purify the required antigen. The 
complexes so formed can be used as an immunogen. A major advantage of designing 
SMAA complexes as vaccines is in the preparation of the immunogen and they permit 
a relatively simple procedure be used for preparation of the antigen. Since these 
complexes are to be used as an immunogen, there is no need to use strong denaturing 
conditions to remove antigen from the complexes. '^ Their property of being 
relatively stable to prolonged storage can be advantageous in developing countries 
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where it may be difficult to store some vaccines/' Also antigens derived from 
virtually any source, be it expression vectors or virus-infected tissue culture cells, can 
simply be incorporated into SMAA complexes/^ SMAA complexes do not appear to 
have been used for inducing immunity against RSV. There would appear to be 
application of this methodology for immunization against this viral infection. The 
potential to induce both cell-mediated and humoral immunity to a specific viral 
protein is encouraging. The approach would allow evaluation of the immunogenicity 
of various structural components of the virus. The best option for future work would 
be to prepare SMAA complexes as reported or use N protein expressed in 
recombinant vaccinia virus. This expressed protein could then be used for 
preparation of immune complexes. Such complexes could then be used to determine 
immunogenicity in calves having maternal immunity. These comparative analyses 
will help to determine the effectiveness of N protein as an immunogen in the 
presence of maternal immunity and may pave the way to a better vaccine for calves 
having maternal immunity, and provide a means for protecting young animals from 
infection with this virus. 
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GENERAL SI3MMARY 
Bovine respiratoiy syncytial virus (BRSV), an important pathogen of cattle, is 
considered to be a major contributor to the incidence of respiratory tract disease in 
nursing beef, feed lot and dairy calves. It causes the greatest morbidity in calves 
during the first six months of life when maternal immunity is still present. 
Reinfections are common and difficulties have been encountered in providing 
protection through live or inactivated vaccines against respiratory syncytial viruses. 
A major limitation of these vaccines is that maternally-derived immunity to BRSV 
suppresses an active immune response to vaccination in calves. The basis for this 
suppression is not well understood. It may result from the blocking effect of the 
specific anti-viral antibodies. 
The purpose of the present investigation was to study the morphogenesis of 
bovine respiratory syncytial virus (BRSV) strain 375, to generate monoclonal 
antibodies (MAbs) against it's N protein, and to use solid matrix-antibody-antigen 
complexes containing N protein of BRSV and a MAb to investigate the 
inununogenicity of the N protein and determine its carrier effect on the subsequent 
vaccination with heat inactivated virus. 
The moiphology of BRSV strain 375, originally isolated from nasal secretions of 
a calf (Lehmkuhl et al. 1979), was observed in Vero cells at a stage when extensive 
cytopathic effects were present. Electron microscopic examination of ultrathin 
127 
sections of BRSV-infected Veto cells revealed not only spherical and filamentous 
forms of the virus but also bridges between.the spherical particles. The bridges did 
not appear to be arranged at a particular angle. Because of the bridges the virus 
particles occurred in large aggregates requiring that this factor be taken into account 
while purifying the virus. Both forms were observed budding from the cell 
membrane of infected cells. Most of the observed mature particles were 
extracellular. However a few spherical particles with and without internal structure 
were also present in intracytoplasmic vesicles. This confirms an earlier report on 
assembly of virus particles intracellularly in Vero cells infected by a member of the 
family Paramyxoviridae. Further studies are indicated, using different cell lines to 
minimize the host cell related variations to arrive at some final conclusion regarding 
the intracytoplasmic maturation of different strains of BRSV. 
A panel of monoclonal antibodies (MAbs), derived from the fusing of the primed 
BALB/C mice spleenocytes to SP2/0 cells, were generated against the N protein of 
BRSV. Different methods were used to immunize the mice for production of 
hybridomas and eventually MAbs. The MAbs were characterized by ELISA, a 
radioimmunoprecipitation assay, indirect inununofluorescence, and epitope mapping. 
According to the class and subclass of Ig these MAbs can be grouped into four 
groups. Eight MAbs, two from each group, were used for epitope mapping. The 
competitive binding assay indicated competing and non competing MAbs. The 
reaction pattern of the MAbs indicated 4 to 6 antigenic sites on the N protein. 
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Immune complexes consisting of radiolabeled BRSV and newly generated N 
protein MAbs, or radiolabeled BRSV and human respiratory syncytial virus N protein 
MAb were mixed and then electrophoresed together to monitor the electrophoretic 
mobility of the precipitated N proteins. Both the N proteins moved together showing 
that they had the same molecular weight (43.4 Kd) and signifymg that the generated 
MAbs were directed against the N protein of BRSV. 
The genome of the respiratory syncytial viruses codes ten proteins including N, a 
structural protein. A number of workers have analyzed the antibody response to N 
protein of human respiratory syncytial virus (HRSV) in experunental animals with 
variable results. The general consensus is that the protection induced by N protein of 
HRSV does not last long and is not as solid as provided by G and F proteins. 
Keeping m view such reports and our own preliminary studies we considered it 
possible to use the N protem of BRSV as vaccine during the early period of the 
calves when they have maternal antibodies against BRSV. But the first thing was 
how immunogenic the N protein is? Since earlier reports indicated that the N protein 
is not highly inraiunogenic we decided to incorporate it in SMAA complexes and use 
these in lambs to determine it's immunogenicity. 
Two monoclonal antibodies 65-12 (IgM) and 38-6 (IgG2a) were used to make 
solid matrix-antibody-antigen complexes (SMAA). The SMAA complexes so formed 
were washed five times with PBS, suspended in an equal quantity of aluminum 
hydroxide gel and used for immunization of two groups of lambs. The immune 
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response was monitored by lymphocyte transforming assay (LTA), western 
immunoblot assay (WIA) and serum neutralization (SN) assay. In immunized groups 
the maximum immune response in terms of lymphocyte blastogenic responses 
(stimulation index) was observed on day 11 postvaccination. However, the response 
of animals in group B, vaccinated with SMAA complexes containing MAb (IgM) was 
significantly higher than the group C, vaccinated with SMAA complexes containing 
MAb (IgGjJ. The group B animals also exhibited a marked humoral response to N 
protein in WIA as compared to group C and control animals 11 days postvaccination. 
None of the animals developed a SN antibody titer after vaccination. Subsequent 
challenge, 21 days postvaccination, with heat inactivated BRSV resulted in a 
better SN titer in the SMAA complexes vaccinated groups than the control group. 
The premise for this experimentation was based on a classical immunologic 
phenomenon observed some 25 years ago and termed the "carrier effect". While the 
mechanistic basis was not clear at the time of the initial observations of this 
phenomenon, subsequent experimentation and increased knowledge of the immune 
system have defined the operational mechanisms. An immune response requires 
cooperation between two or more populations of cells including for a humoral 
response an antigen presenting cell, a helper T lymphocyte and a B lymphocyte. The 
T lymphocyte reacts to immunogenic determinants associated with the carrier moiety 
of the antigen while the B cell recognizes and responds to haptenic determinants. The 
latter responds with the production of antibodies but usually only when T cell help is 
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available. A virus consists of multiplicity of immunogenic and haptenic epitopes and 
it is possible that a B cell could receive help from T cells responding to a variety of 
different inununogenic determinants. Consequently, it was theorized that T cells 
primed to one protein component of a virus might provide enhanced help to B 
lymphocytes responding to another component of that virus. 
The hypothesis for this experimentation was that immunization with a protein of 
BRSV would prime these animals for subsequent secondary responses to not only the 
N protein but other structural components of the virus. The results of this 
experimentation are extremely promising. The N protein was quite inununogenic 
when administered as an SMAA complex and induced both humoral and cell-
mediated responses. These complexes are easily prepared and administered. 
Secondary or booster inmiunization with intact, killed virus induced vigorous 
antibody responses. The nature and degree of this response in previously vaccinated 
animals as compared to controls is indicative of a secondary immune response. This 
result was to be expected with the response to N protein but obviously the response 
extended to other antigenic components of the virus. This was indicated by the level 
of antibodies in sera as detected by WIA but most importantly, by the dramatic rise 
in the titers of neutralizing antibodies. Neutralizing epitopes of this virus are 
associated with the F and G glycoproteins (not N protein) which can be regarded as 
protective antigens. The important consideration is that animals can be primed for a 
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response to these antigens without incorporating those antigens in the primary 
immunogens. Thus, we have confirmed our experimental hypothesis. 
The question to be resolved is the potential application of this methodology to 
immunization of calves with residual maternal antibodies. Available evidence 
indicates that calves derive antibodies directed against several viral proteins fi-om 
their dams. However, antibodies directed against the F protein are usually highest in 
titer with resultant persistence of these antibodies for several months in the blood 
circulation of the calf. Antibodies to the N protein are present at lower levels and, 
consequently, do not tend to persist in the calf. This situation should permit 
immunization of calves at a relatively early age with a vaccine composed of N 
protein. This could potentially induce some protection against viral infection but also 
would prime these calves for a secondary immune response. Administration of a 
second vaccine composed of intact virions could be expected to induce solid 
protection against infection by the virus. 
While this immunization protocol would seem to have great potential, one aspect 
of the approach could be the basis for a problem. Vaccines containing proteins of 
foreign species are widely recognized for eliciting hypersensitivity reactions. The 
SMAA complexes utilized in these studies contained MAbs of mouse origin. The 
development and use of MAbs of ovine or bovine origin could be a preferred 
approach. 
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